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ABSTRACT 
ROLE OF JMJD5 IN LIVER CANCER  
Engin Demirdizen 
M.S. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
August 2013, 94 Pages 
 
Being one of the most common cancer types in human population, hepatocellular 
carcinoma (HCC) has high rate of deaths due to the challenges in its diagnosis and 
treatment. In recent years, epigenetic regulators have come into play in HCC 
research to overcome with those challenges. As potential drug targets, histone 
demethylases has drawn a lot of interest. In this respect, several studies have focused 
on a specific member of this family, JMJD5, suggesting its possible function in 
tumor suppression, while the opposite argument has also been proposed by several 
reports. Preceding studies on JMJD5 in our lab also pointed to a possible tumor 
suppressor function. Hence, this study aimed to elucidate the role of JMJD5 in liver 
cancer development using SNU449 HCC cell line stably expressing JMJD5. For this 
purpose, stable clones overexpressing wild-type and mutant JMJD5 as well as 
controls were generated. A comparative analysis of these clones was performed. No 
definite results could be obtained for the effect of JMJD5 on cell proliferation, but 
the number of cells in G1 declined, whereas that in G2/M inclined in clones 
expressing wild-type and mutant JMJD5, suggesting that JMJD5 affects cell cycle 
progression. In addition, cell motility was decreased, while anchorage-independent 
colony formation ability was enhanced in both mutant and wild type JMJD5-
expressing clones. Decrease in cell motility is considered to be anti-tumoral, whereas 
anchorage-independent growth is a malignant change. Our findings suggest that 
JMJD5 may have a quite complex role in liver tumorigenesis. Further in vivo studies 
may help to clarify some of these apparently conflicting in vitro effects. 
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ÖZET 
JMJD5’İN KARACİĞER KANSERİNDEKİ ROLÜ 
Engin Demirdizen 
Moleküler Biyoloji ve Genetik, Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Ağustos 2013, 94 Sayfa 
 
İnsan popülasyonunda en sık görülen kanser tiplerinden biri olarak, teşhis ve 
tedavisindeki zorluklardan dolayı karaciğer kanseri (Hepatoselüler Karsinom, HSK) 
yüksek ölüm oranına sahiptir. Bu zorlukların üstesinden gelebilmek için son yıllarda 
HSK araştırmalarında epigenetik düzenleyiciler kullanılmaya başlandı. Potensiyel 
ilaç hedefleri olarak histon demetilazlar çok ilgi çekmektedir. Bu bakımdan, pek çok 
çalışma karşıt delilleri de diğer çalışmalarda iddia edilmesine rağmen tümör 
baskılanmasında olası bir görevi olduğunu ileri sürerek bu ailenin bir üyesi olan 
JMJD5’e odaklanmıştır. Labımızda JMJD5 üzerindeki daha önce yapılan çalışmalar 
da olası bir tümor baskılama görevine işaret etmiştir. Bu yüzden bu çalışma JMJD5’i 
stabil olarak ifade eden SNU449 HSK hücre hattını kullanarak JMJD5’in karaciğer 
kanseri gelişimindeki rolünü ortaya çıkarmayı amaçlamıştır. Bu amaç için normal ve 
mutant JMJD5’i olduğundan fazla ifade eden stabil klonlarla birlikte kontroller 
oluşturuldu. Bu klonların kıyaslamalı analizi yapıldı. JMJD5’in hücre çoğalmasına 
etkisi hakkında kesin sonuçlar elde edilemedi, ancak G2/M’deki hücre sayısı normal 
ve mutant JMJD5 ifade eden klonlarda artarken, G1’deki hücre sayısı azaldı. Bu 
sonuç JMJD5’in hücre döngüsü ilerleyişini etkilediğini ileri sürüyor. Buna ek olarak, 
mutant ve normal tip JMJD5 ifade eden klonlarda dayanaktan bağımsız koloni 
oluşum kapasitesi artarken hücre hareketliliğinin azaldığı gözlendi.. Hücre 
hareketliliğinde azalma tümör önleyici olarak düşünülürken dayanaktan bağımsız 
büyüme kötü huylu bir değişimdir. Bulgularımız JMJD5’in karaciğer kanseri 
oluşumunda oldukça karmaşık bir rolü olabileceğine işaret ediyor. Daha fazla in vivo 
çalışma, görünüşe göre çelişkili in vitro etkilerin bazılarına açıklık getirmeye yardım 
edebilir. 
Anahtar sözcükler: JMJD5, karaciğer kanseri, hepatoselüler karsinom, tümör         
baskılayıcı.  
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CHAPTER 1 
INTRODUCTION 
1.1 Hepatocellular carcinoma 
Among all types of liver cancer, hepatocellular carcinoma (HCC) is the most widely 
encountered, comprising 83 % of all cases [1]. As a common disease, HCC is the 
fifth and seventh most widespread cancer in populations of men and women, 
respectively [2].  Being the sixth most prevalent neoplasm, HCC is also ranked third 
among the cancers most frequently causing death, with only 14 % 5-year survival 
rate [3, 4].  
1.1.1 Aetiologies of hepatocellular carcinoma 
The major aetiological factors regarding HCC include infection with hepatitis B 
(HBV) and C virus (HCV), contributing to about 70 % of all cases, excessive alcohol 
intake and aflatoxin contamination in the food resources [1, 2, 5]. Other risk factors, 
including female oral contraceptive use for a long time, certain metabolic diseases, 
diabetes, obesity, non-alcoholic fatty liver disorders (NAFLD) and non-alcoholic 
steatohepatitis, are also minorly responsible for the causation of HCC [1, 5]. The 
frequency of HCC occurrence changes in the world based on geographical 
distribution of causative agents. HBV infection plays a major role in most Asian and 
African countries, whereas HCV infection is the primary reason for HCC in United 
States and most European countries. Heavy alcohol drinking in western societies and 
dietary aflatoxin contamination in South China and Sub-Saharan Africa are primary 
causes of HCC development in these regions [2]. 
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1.1.2 Pathogenesis of hepatocellular carcinoma 
The cause of hepatocellular carcinoma can be literally attributed to cirrhosis-
stimulating circumstances in the host microenvironment [1]. HBV-HCV infections 
and alcohol overconsumption lead to inflammation, many rounds of hepatocyte loss 
and regeneration, oxidative stress and permanent fibrotic activity, ultimately 
resulting in cirrhosis [1, 6]. After liver is injured, genomic stability is lost through 
blockage of DNA repair, carcinogenic agents and epigenetic alterations, which starts 
conversion of normal hepatocytes into malignancy [6, 7]. As the genetic damage 
accumulates, self-expanding dysplastic nodules arise, and they progressively give 
rise to well-differentiated, moderately differentiated and poorly differentiated 
metastatic HCC [7].  
Genomic changes, including chromosome abnormalities and genetic mutations are 
commonly observed in HCC [1]. Loss of 4q and gain of 1q, 8q, 17q are the most 
widespread changes in the chromosome [5]. Mutations detected in HCC cases mainly 
occur in p53, β-catenin, Axin1, p16, hTERT, ErbB receptor family and MET 
receptor [1, 5, 8]. Epigenetic mechanisms, such as DNA methylation, mutations in 
epigenetic factors and differential expression of miRNAs, have been found to be 
associated with HCC pathogenesis [5]. As a key component in HCC development, 
inhibition of p53 and p16, coupling with hTERT activation, drives liver cells into 
bypassing senescence and immortalization [9].                
1.2 Epigenetics, cancer and HCC 
The field of hereditary alterations which do not occur in base sequence of DNA but 
affect gene expression is defined as epigenetics [10].  This inherited knowledge is 
encoded by chemically modified nucleotides and proteins binding to the chromatin in 
eukaryotic genomes. Gene expression patterns are deeply differentiated upon 
epigenetic changes because accessibility of genes and chromatin architecture are 
modulated [11]. There are four major mechanisms of epigenetic modification: DNA 
methylation, covalent modifications of histones, microRNAs and non-covalent 
actions of nucleosome remodeling machineries and histone variants [10]. 
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Abnormal functioning in epigenetic mechanisms is equally important as genetic 
events in the onset and development of carcinogenesis [12]. As evidence suggests, 
the function of key epigenetic players changes earlier than cell transformation into 
malignancy, thereby playing a critical role in cancer development [13, 14]. In terms 
of discovery of early diagnostic biomarkers, risk consideration and tracing of the 
disease, more elaborated knowledge on epigenetic mechanisms could provide 
promising improvements [13].  
Methylation patterns of genome, histone modification status and expression levels of 
chromatin-regulating factors are globally altered in cancer epigenome [10]. 
Hypomethylation in the global scale and hypermethylation in the CpG islands of 
tumor suppressor promoters are commonly detected in the cancer cells [10, 12]. 
According to mapping studies covering whole chromatin, most widely observed 
histone modifications in cancer are diminished histone-4 lysine 16 acetyl (H4K16ac), 
H4K20 methyl (H4K20me3) levels and varying H3K9, H3K27 methylations, all of 
which leads to gene silencing. Upregulated histone deacetylases (HDACs) levels, 
changing histone acetyl transferases (HATs) levels and aberrant histone 
methyltransferases (HMTs) activity underlie those modifications, being other 
characteristics of cancer. Histone lysine demethylases (HDMs), many of which 
possess Jumonji C domain, have also been associated with cancer, several of them 
being upregulated in prostate cancer. Nucleosome remodeling complexes were 
shown to act together with DNA methylations and histone modifications on silencing 
of tumor suppressors via compacting nucleosome settlement in promoter regions. 
Compared to normal tissues, miRNA expression levels also exhibit wide range of 
changes in tumor [10].     
In the context of HCC, DNA methylation abnormalities, influencing mutations in 
epigenetic factors and changes in miRNA expression profiles have newly been 
identified with a raising concern [5]. Promoter hypermethylation in tumor suppressor 
genes and genome-wide hypomethylation have been characterized in HCC [15]. 
EZH2, which constitutes the catalytic part of polycomb repressive complex 2 (PRC2) 
and generates H2K27me3 repressive mark, is upregulated in HCC and correlates 
with the aggresiveness of HCC [5, 16]. HDACs-1, -2 and -3; enzymes involved in 
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DNA methylation, including DNMT1, DNMT3A and DNMT3B; and CENPA 
histone variant levels have also been shown to exhibit elevation in HCC samples 
compared to non-tumor liver samples [5].      
1.3 Histone demethylases 
Similar to the histone methylation through histone methyltransferases, which 
regulate chromatin architecture and transcription, HDMs play key functions in the 
cellular mechanisms, including development and involvement in disease. Histone 
demethylases so far identified have been shown to be important in normal processing 
of the cells, playing a diverse range of biological roles and also targeting non-histone 
proteins as substrates [17].  
1.3.1 Histone lysine demethylase (HDM) family 
Recently discovered histone lysine demethylases including amine oxidase family and 
Jumonji C (JmjC) domain-containing enzyme family has proved that histone lysine 
methylation is reversible. The first member of histone lysine demethylases 
discovered was lysine-specific demethylase 1(LSD1), also known as KDM1 [18]. 
The first member to be elucidated in JmjC family was F-box and Leu-rich repeat 
protein 11 (FBXL11), also known as JHDM1A and KDM2A, which was reported to 
demethylate H3K36me1 and H3K36me2 [17]. With the discovery of JMJD2, which 
is capable of demethylating H3K9me3/me2 and H3K36me3/2, and many others, 
trimethylation on histone lysine residues were also indicated to be reversible [19].  
Up to now, demethylation events targeting H3K4, H3K9, H3K27, H3K36 and 
H4K20 have been detected in 18 members of 30-member JmjC family, as 
summarized in Table 1.1 [17]. 
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Table 1.1: List of histone lysine demethylases, their specific substrates and related diseases.  
(Adapted from Kooistra and Helin, 2012 [17])  
Name  Synonyms  Histone 
substrates 
Non-
histone 
substrates  
Association with human disease  
 
LSD demethylases  
LSD1  AOF2, 
BHC110, 
KDM1A  
H3K4me1, 
H3K4me2, 
H3K9me1, 
H3K9me2  
p53, E2F1, 
DNMT1  
Overexpression in prostate cancer, 
undifferentiated malignant 
neuroblastoma, oestrogen-receptor-
negative breast cancer, bladder 
cancer, lung and colorectal carcinoma 
and silencing/downregulation in 
breast cancer  
LSD2  AOF1, 
KDM1B  
H3K4me1, 
H3K4me2  
 Amplification and overexpression in 
urothelial carcinoma  
JMJC demethylases  
JMJD7      
HIF1AN      
HSPBAP1     
JMJD5  KDM8  H3K36me2    
JMJD4      
JMJD6  PSR, 
PTDSR  
H3R2, H4R3   Overexpression in chronic pancreatitis 
 
JMJD8      
FBXL10  JHDM1B, 
KDM2B 
H3K36me1, 
H3K36me2, 
H3K4me3  
 Overexpression in various leukaemias 
and bladder carcinoma  
FBXL11  JHDM1A, 
KDM2A  
H3K36me1, 
H3K36me2  
p65, NF-
κB  
 
KIAA1718  JHDM1D H3K9me1, 
H3K9me2, 
H3K27me1, 
H3K27me2  
  
PHF8  JHDM1F H3K9me1, 
H3K9me2, 
H4K20me1  
 Mutation and deletion associated with 
X-linked mental retardation and cleft 
lip/palate  
PHF2  JHDM1E  H3K9me2  ARID5B  Mutation or silencing/downregulation 
in breast carcinoma and head and 
neck squamous cell carcinoma  
HR      
KDM3B      
JMJD1A  JHDM2A, 
TSGA, 
KDM3A 
H3K9me1, 
H3K9me2 
 Overexpression in malignant 
colorectal cancer, metastasized 
prostate adenocarcinoma, renal cell 
carcinoma and hepatocellular 
carcinoma  
JMJD1C      
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JMJD3  KDM6B H3K27me2, 
H3K27me3  
 Overexpression in various cancers 
including lung and liver carcinomas 
and several haematological 
malignancies, in neutrophils of 
patients with ANCA vasculitis and in 
primary Hodgkin’s lymphoma  
UTX  KDM6A H3K27me2, 
H3k27me3  
 Mutation in multiple tumour types 
including multiple myeloma, 
oesophageal squamus cell carcinoma, 
renal clear cell carcinoma, transitional 
cell carcinoma, chronic 
myelomonocytic leukaemia, 
overexpression in breast cancer and 
deletion in Kabuki syndrome  
UTY      
JMJD2A  JHDM3A, 
KDM4A 
H3K9me2, 
H3K9me3, 
H3K36me2, 
H3K36me3, 
H1.4K26me2, 
H1.4K26me3  
 Silencing/downregulation in bladder 
cancer and overexpression in breast 
cancer  
 
JMJD2C  JHDM3C, 
GASC1, 
KDM4C 
H3K9me2, 
H3K9me3, 
H3K36me2, 
H3K36me3, 
H1.4K26me2, 
H1.4K26me3 
 Amplification in oesophageal cancer, 
breast cancer, medulloblastoma and 
translocation in lymphoma  
 
JMJD2B  JHDM3B, 
KDM4B  
H3K9me2, 
H3K9me3, 
H3K36me2, 
H3K36me3, 
H1.4K26me2, 
H1.4K26me3 
 Overexpression in malignant 
peripheral nerve sheath tumour  
 
JMJD2D  JHDM3D, 
KDM4D  
H3K9me2, 
H3K9me3, 
H3K36me2, 
H3K36me3, 
H1.4K26me2, 
H1.4K26me3 
  
JARID1B  PLU1, 
KDM5B  
H3K4me2, 
H3K4me3  
 Overexpression in bladder cancer, 
prostate cancer and breast cancer  
JARID1C  SMCX, 
KDM5C  
H3K4me2, 
H3K4me3  
 Mutation in mental retardation, in 
autism and in renal carcinoma  
JARID1D  SMCY, 
KDM5D  
H3K4me2, 
H3K4me3  
 Deletion in prostate cancer  
 
JARID1A  RBP2, 
KDM5A  
H3K4me2, 
H3K4me3  
 Silencing/downregulation or deletion 
in melanoma, translocation in acute 
leukaemia and mutation in ankylosing 
spondylitis  
JARID2     Mutation associated with non-
syndromic cleft lip, spina bifida and 
congenital heart defects  
7 
 
MINA      
NO66   H3K4me2, 
H3K4me3, 
H3K36me2, 
H3K36me3  
 Overexpression in non-small cell lung 
cancer  
 
1.3.2 Regulation of histone demethylase activity 
Several mechanisms that control histone demethylase activity include modulation of 
gene expression, settlement into the target via certain domains or as a component of 
protein complexes and modifications at the post-translational level [17, 20]. For the 
recruitment of the enzyme to the histones, high numbers of weak associations in the 
chromatin surroundings are utilized [18]. It turned out that in their recruitment sites, 
in place of switching on/off activity, they are involved in fine-tuning of the 
transcriptional regulation [17]. 
1.3.3 Biochemical mechanism of histone lysine demethylation 
LSD1 carries out demethylation through flavin adenine dinucleotide (FAD)-
dependent amine oxidation. In this mechanism, imine intermediate is formed due to 
oxidation of target methyl group on lysine by FAD, which is followed by hydrolysis 
of the intermediate product and release of demethylated lysine and formaldehyde. 
Because of chemical restrictions, LSD1 could only conduct its function on lysines 
with mono or dimethylation, whereas JmjC domain-containing histone lysine 
demethylases (JHDMs) catalyze the reaction at all three levels of histone 
methylation. In JHDM mechanism, target methyl group is converted into a 
hydroxymethyl group, with the involvement of α-ketoglutarate (α-KG) and Fe2+ as 
cofactors; then release of the hydroxymethyl group in formaldehyde form occurs, 
generating unmethylated lysine residue [18]. 
1.3.4 HDMs in relation to cancer 
Several lines of study point to the fact that genetic changes and protein deregulations 
in histone demethylases are commonly encountered in cancer and these proteins are 
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considered as targetable candidates for drug research [19].  Suppressive effect of 
LSD1 on p53 and E-cadherin proposes that it might stimulate tumorigenesis [17, 21]. 
JMJD2 proteins, namely JMJD2A, JMJD2B and JMJD2C, have potentially 
oncogenic property, as evidenced by high expression of all in prostate cancer and 
contribution of JMJD2C to the cancer cell proliferation [19]. In breast cancer cells, 
JARID1B was shown to be upregulated [21]. In a hematopoetic mouse model, 
mutation in FBXL10 was detected, suggesting its possible tumor suppression 
activity. Upon triggering of senescence depending on RAS oncogene induction in 
primary human epithelial cells, JMJD3, JMJD6 and KIAA1718 were shown to be 
overexpressed, addressing a possible involvement of these factors in inducing 
senescence [19]. 
1.4 Role of JMJD5 in H3K36 demethylation and protein 
hydroxylation 
1.4.1 Role of JMJD5 in histone demethylation  
1.4.1.1 Biological importance of H3K36 methylation 
Histone methyltransferases known as SET2/KMT3 family carry out H3K36 
methylation, which is generally found in body region of transcriptionally active 
genes. Consistently, this mark has been proposed to function in elongation of 
transcripts and inhibition of transcriptional start in this region [22]. Being related to 
actively transcribed chromatin in majority of the cases, methylation at H3K36 is also 
known to play roles in silencing of extra X chromosome, replication of DNA, DNA 
damage response, alternative splicing and methylations of DNA [23]. 
1.4.1.2 JMJD5 in the literature 
JMJD5 was first demonstrated to play a role in connection between histone 
modulation and circadian clock regulation, having an evolutionary conservation from 
plants to humans [24]. In Arabidopsis, JMJD5 accumulation in both cytoplasm and 
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nucleus was detected, suggesting differential roles in both regions [25]. JMJD5, 
depending on its localization, might be carrying out protein hydroxylation in soluble 
part of nucleus and histone demethylation in chromatin [26]. According to the 
preliminary analyses, presence of an LXXL motif on N-terminus of JMJD5, required 
for interaction with nuclear receptors; and association with SUV39H1 and SETDB1 
histone methyltransferases were predicted, implying complicated regulatory 
mechanisms [27]. Biochemical and functional analyses on JMJD5 revealed that it 
could most probably act as a protein hydroxylase rather than histone demethylase 
[28]. Hydroxylating NFATc1 and leading to its degradation, JMJD5 suppresses 
differentiation of precursor osteoclasts [26].   
Through removing methyl marks on H3K36me2, JMJD5 induced cyclin A1 
expression, functioning as a key factor in cell cycle progression of breast cancer cells 
[27].  JMJD5 deletion in mouse embryos resulted in an embryonic lethal phenotype 
due to the overexpression of Cdkn1a gene, which encodes p21
cip1
 cyclin-dependent 
kinase inhibitor, through demethylation of H3K36 [29]. As a potential oncogene, 
JMJD5 was also proposed to inhibit p53-p21
cip1
 pathway and p53-mediated cell cycle 
arrests in mouse embryos [30]. In contrast, histone demethylase-free action and 
decreased JMJD5 expression in lung cancer was detected, suggesting a possible 
function in tumor inhibition [31]. Furthermore, in an insertional mutagenesis study 
using mice lacking Blm, JMJD5 was identified as a candidate tumor suppressor [32]. 
1.4.2 Role of JMJD5 in protein hydroxylation 
Metazoans, ranging between worms and humans, have a set of adaptive mechanisms 
against low oxygen conditions primarily controlled by hypoxia-inducible factor-α   
(HIF-α in short) [33]. The putative oncogenic roles of many HIF-target genes and 
elevated expression of HIF-α on several solid tumors suggest its potential tumor-
inducing role [34]. Its accumulation, interaction with other partners and degradation 
are regulated by HIF-prolyl hydroxylases (HPHs), which constitute a subfamily 
among dioxygenases. These enzymes were also described in HIF-independent 
hydroxylation activities on several other substrates [33]. Exemplifying the first 
discovered protein hydroxylation event in the cell, HIF-α hydroxylation is performed 
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by EGLN hydroxylases on proline residue at high levels of oxygen and by factor-
inhibiting HIF-α (FIH) on asparagine residue at intermediate levels of oxygen [35]. 
1.4.2.1 Hydroxylation activities of JMJD5 and its related proteins 
Biochemical analysis on JMJD5 structure suggests a possible protein hydroxylase 
function rather than histone demethylation [28]. Recently, it was also documented 
that JMJD5 hydroxylates NFATc1 (nuclear factor of activated T-cells calcineurin-
dependent 1), a critical transcription factor in osteoclastogenesis, and helps its 
proteasomal degradation [26]. Consistently, JmjC domain-containing enzymes 
involved in protein and nucleic acid hydroxylation, such as FIH-1, JMJD6, TWY5 
and HSPBAP1 seem to be more homologous to JMJD5 depending on structural and 
sequential comparisons [28]. FIH-1 is responsible for the hydroxylation of HIF-α at 
Asparagine 803 under medium level of oxygen, resulting in HIF-α inhibition [19]. 
JMJD6 was detected to act as a lysyl hydroxylase on an RNA splicing protein 
U2AF65 (U2 small nuclear ribonucleoprotein auxiliary factor 65-kDa subunit), and 
its previously documented histone arginine demethylation role was disproved [36]. 
TYW5 (tRNA yW-synthesizing enzyme 5) was reported to catalyze hydroxylation of 
wybutosine (yW), a nucleoside located in tRNA
Phe
 whose modification is required 
for proper translation of phenyl alanine, to its derivative [37]. HSPBAP1 (heat-shock 
protein 27 (Hsp27) -associated protein 1) was put forward as a potential protein 
hydroxylase of Hsp27 to block its activity [19].  
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CHAPTER 2 
OBJECTIVES AND RATIONALE 
Due to the absence of early biomarkers, liver injury-related restrictions on drug use 
and resistance against cytotoxic agents used for cancer therapy; HCC is lethal. As the 
genetic, molecular and aetiological mechanisms are better understood, the severe 
problems that liver cancer therapy is confronted could be dealt with [1]. Epigenetics, 
in this perspective, could provide progression in discovery of early diagnostic 
biomarkers, risk consideration and tracing of the disease [13]. In particular, several 
lines of study point to histone demethylases as targetable candidates for drug 
research [19]. JMJD5, a member of JmjC domain-containing histone lysine 
demethylase family, has recently been suggested to have a putative tumor suppressor 
role [31, 32]. Our past and current group members have also demonstrated its 
downregulation from the early onset of liver disease to hepatocellular carcinoma (see 
Figures 4.2 and 4.3 in "Results" section), suggesting a key role for this gene in 
normal functioning of liver and hepatocarcinogenesis. These results led to come up 
with the hypothesis that JMJD5 might have a tumor suppressor function in liver, its 
deficiency possibly contributing to the development of liver disease and carcinoma. 
In this study, we aimed at analysis of biological roles of JMJD5, with a particular 
focus on its tumor suppressor activity, applying genetic, molecular biological, 
phenotypic and morphological assays using hepatocellular carcinoma-derived 
SNU449 cell line. The outcomes of this study are expected to make important 
contributions to the liver cancer research in regards of candidate drug targets and 
biomarker identification.    
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 General Laboratory Reagents  
The chemicals majorly used in this research were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and Merck (Darmstadt, Germany). The commonly used reagents, 
including ethanol, methanol, haematoxylene and Bradford reagents, were from 
Sigma-Aldrich (St. Louis, MO, USA). Ponceau S and DMSO were purchased from 
Applied Biochemia (Darmstadt, Germany). Nucleospin RNA II total RNA isolation 
kit and plasmid mini-prep kit was from Macherey-Nagel (Duren, Germany). Plasmid 
midi-prep kit was bought from Promega (Madison, WI, USA). Fluorescent mounting 
medium was from Dako. ECL Prime detection kit used for western blot was from 
Amersham Pharmacia Biotech Company (Buckinghamshire, UK). Agarose used in 
gel electrophoresis was purchased from Conda (Madrid, Spain). Agar, yeast extract 
and tryptone were puchased from Gibco (Carlsbad, CA, USA).  
3.1.2 Cell culture materials and reagents  
All the plastic equipments, including petri dishes, plates, flasks and cryovials, were 
bought from Corning Life Sciences Incorporated, (Corning, NY, USA). Dulbecco’s 
modified Eagle’s medium (DMEM) and Roswell Park Memorial Institute (RPMI) 
1640 media were purchased from GIBCO (Life Technologies, Carlsbad, CA, USA). 
Powder DMEM High Glucose was from USBiological (Swampscott, Massachusetts, 
USA). Non-essential amino acids, trypsin-EDTA, penicillin/streptomycin, L-
glutamine, fetal bovine serum (FBS), Optimem reduced serum medium, puromycin 
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and blasticidin were all from GIBCO. Serological pipettes and sealed-cap 
polycarbonate centrifuge tubes were from Costar Corporation (Cambridge, UK). 
Lipofectamine 2000 was purchased from Invitrogen. 
3.1.3 Bacterial Strains 
E. coli DH5α strain was used in this study.   
3.1.4 Nucleic acids 
DNA molecular weight markers and 6X loading dye were purchased from MBI 
Fermentas GmbH (Germany). pLTRE-FLAG-KDM8, pLTRE-FLAG-KDM8H321A 
and pLTRE-FLAG-empty plasmids were constructed and donated by Yoshihiro 
Izumiya from Sacramento, CA, USA. 
3.1.5 Electrophoresis, photography and spectrophotometry 
Agarose gel electrophoresis apparatus was from Thermo Electron Corporation. Gel 
imaging software, power supplies Power – PAC200 and Power – PAC300 were from 
Bio Rad Laboratories (CA, USA). Beckman Du640 UV-visible spectrophotometer 
from Beckman Instruments Incorporation (CA, USA) was used for Bradford assay to 
quantify proteins. Nucleic acid concentrations were determined by using NanoDrop 
from Thermo Scientific (Wilmington, USA).    
3.1.6 Antibodies 
Antibodies used in different assays are indicated in the following table together with 
their catalog numbers, and working dilutions. 
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Table 3.1: The list of the antibodies with their catalog numbers and working dilutions  
(WB: western blotting, IP: immunoperoxidase staining, FC: flow cytometry, IF: immunofluorescence) 
Antibody Company and catalog 
number 
Dilution 
Calnexin (rabbit, 
polyclonal) 
Sigma, C4731 1:5000 (WB) 
Anti-mouse-HRP Sigma, A0168 1:5000 (WB) 
Anti-rabbit-HRP Sigma, 6154 1:5000 (WB) 
Anti-rabbit/Mouse HRP 
link 
Dako, K8000 Working solution was 
used without dilution.  
Flag M2 (mouse, 
monoclonal) 
Sigma, F1804 1:1000 (WB), 1:200 (IP), 
1:200 (FC), 1:200 (IF) 
IgG1-FITC isotype 
control (mouse, 
monoclonal) 
Immunotools, 21275513 1:25 (FC) 
Anti-mouse-FITC Dako, F0479 1:250 (FC) 
JMJD5 (rabbit 
polyclonal) 
Abcam, ab83011 1:1000 (WB) 
BrdU (mouse, 
monoclonal) 
Dako, M0744 1:500 (IF) 
Flag (rabbit, 
polyclonal) 
Sigma, F7425 1:500 (IF) 
Anti-mouse Alexa 
Fluor 488 
Invitrogen, A11029 1:500 (IF) 
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Anti-rabbit Alexa Fluor 
568 
Invitrogen, A11011 1:500 (IF) 
3.2 SOLUTIONS AND MEDIA 
3.2.1 General solutions  
50X Tris Acetate EDTA (TAE) 242 g Tris base, 57.1 ml glacial acetic 
acid and 18.6 g EDTA were dissolved in 
1 liter ddH2O. 
1X working dilution is used.  
10X Phosphate Buffered Saline (PBS) 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 
2.4 g KH2PO4 in 1 liter ddH2O 
1X working dilution is used. Before use 
in cell culture, it is autoclaved.  
Ethidium bromide  10 mg/ml stock is prepared by dissolving 
in ddH2O. 
Working concentration is 30 µg/ml. 
3.2.2 Bacteria solutions  
Luria-Broth (LB) medium 10 g bacto-tryptone, 5 g bacto-yeast 
extract and 10 g NaCl were dissolved in 
1 liter of water.  For LB agar plates, 15 
g/L bacto agar was added and autoclave-
sterilized.   
Ampicillin  100 mg/ml stock solution was dissolved 
in ddH2O. 
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100 µg/ml working concentration was 
used. 
3.2.3 Immunofluorescence staining solutions 
Acetone: methanol fixation reagent Acetone and methanol were mixed in 1 
to 1 ratio. 
  
Blocking solution 10% FBS, 0.3% Triton X-100 in 1X 
PBS 
 
Antibody dilution solution 
 
1 % BSA, 0.3% Triton X-100 in 1X PBS  
DAPI (4’,6-diamino-2-phenylindole) 0.1-1 µg/ml working concentration in 
ddH2O. 
3.2.4 Immunoperoxidase staining solutions 
Acetone: methanol fixation reagent Acetone and methanol were mixed in 1 
to 1 ratio. 
3% H2O2 solution It was prepared mixing 30% H2O2 with 
methanol and ddH2O. (For example, 3 
ml H2O2, 10 ml methanol and 17 ml 
ddH2O)    
Blocking solution 10% FBS, 0.3% Triton X-100 in 1X 
PBS 
DAB solution DAB chromogen and its substrate from 
Dako were used according to the 
manufacturer’s protocol.  
DAPI (4’,6-diamino-2-phenylindole) 0.1-1 µg/ml working concentration in 
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ddH2O. 
3.2.5 BrdU incorporation assay solutions 
BrdU Stock solution concentration is 10 mg/ml 
in ddH2O. 30 µM working concentration 
is used. 
2N HCl  8.62 ml of 37% HCl is added to 16.36 
ml ddH2O.  
3.2.6 Sodium Deodecyl Sulphate (SDS) – Polyacrylamide Gel Electrophoresis 
(PAGE) and immunoblotting solutions  
In this study, tris-glycine gels and buffers were prepared manually according to a 
conventional protocol in our lab. To prepare 5% stacking gel, ddH2O, 30% 
acrylamide mix, 1.0 M Tris-HCl pH 6.8, 10% SDS, 10% ammonium persulphate and 
TEMED were mixed successively, in certain volumes. For the resolving gel, 
depending on concentration of the gel, same solutions were mixed in certain 
volumes, this time using 1.5 M Tris-HCl pH 8.8 instead of 1.0 M Tris-HCl pH 6.8. 
Wet transfer was applied on PVDF membrane. 5X sample loading buffer, and 
denaturing agent (β-mercaptoethanol) were purchased from Invitrogen.  
NP-40 lysis buffer 50 mM Tris HCl, 150 mM NaCl, 1% 
NP-40, 0.1% SDS, 1X protease inhibitor 
cocktail  
10X SDS Running buffer 
 
144 g glycine and 30 g Tris were 
dissolved in dH2O, 50 ml 10% SDS was 
added, and the volume was completed to 
1 L.   Working solution is 1X. 
10X Transfer buffer  72 g glycine and 58 g Tris were 
dissolved in dH2O, 2 ml 10% SDS was 
18 
 
added, and the volume was completed to 
1 L.   Working solution is 1X containing 
20% EtOH.  
10X Tris buffered saline (TBS) 12.19 g trisma base and 87.76 g NaCl 
were dissolved in 1 L of ddH2O, and pH 
is adjusted to 8.  
Working concentration is 1X.  
  
TBS-tween 20 (TBS-T) 0.2% Tween 20 was dissolved in 1X 
TBS.  
Blocking solution 5% (w/v) non-fat dry milk was dissolved 
in 0.2% TBS-T. 
Ponceau S  0.1% (w/v) Ponceau S and 5% (v/v) 
acetic acid were dissolved in 0.2 % TBS-
T. 
3.2.7 SRB assay solutions 
10 % TCA fixation solution 10 % TCA is dissolved in water. 
0.4 % SRB staining buffer 
 
Tris base, unbuffered 
0.4 % SRB dye powder is dissolved in 1 
% acetic acid.  
10 mM, pH 10.5 
3.2.8 Wound healing assay solutions 
Crystal Violet solution 
 
1 % crystal violet solution is prepared in 
2 % ethanol.  
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3.2.9 Flow cytometry analysis solution 
Propidium iodide buffer 
 
50 µg/ml propidium iodide, 0.1 mg/ml 
RNase A and 0.5% TritonX-100 in PBS 
3.3 METHODS 
3.3.1 Commonly used methods 
3.3.1.1 Agarose gel electrophoresis 
Restriction enzyme digestion products and plasmid DNAs generally were run, 
separated and checked with this technique. Agarose gels were prepared in desired 
weight/volume concentrations by dissolving agarose in 1X TAE buffer using 
microwave heat. When the solution was cool enough, ethidium bromide, reaching to 
30 µg/ml concentration, was added. 1X TAE buffer was also used for the gel run. 
Mixed with 6X loading dye, samples were loaded into the wells and run at 120 V, for 
the various time durations with respect to the size of the products. Visualization of 
DNA fragments was carried out by gel imaging device under UV light, and product 
sizes were compared with those of DNA ladder.  
3.3.1.2 Computer and Software Tools 
NCBI website at http://www.ncbi.nlm.nih.gov/ and Ensembl Genome Browser 
website at http://www.ensembl.org/index.html/ were utilized to learn all sequences, 
transcripts variants exon-intron information about the genes. PROSITE internet tool 
at http://prosite.expasy.org/ developed by Swiss Institute of Bioinformatics 
(Lausanne) was used for conserved domain search. A plasmid Editor (ApE) 
programme created by M. Wayne Davis was used for plasmid map construction, 
restriction digestion design and cloning. 
20 
 
3.3.2 Constructing the plasmids 
The plasmids donated by Yoshihiro Izumiya were constructed by this group in a set 
of cloning processes. 3X Flag tag and RsrII site was inserted into the multiple 
cloning site of pcDNA5/FRT/TO vector (Invitrogen) under CMV promoter 
containing Tet operator sequences. JMJD5 variant 2 open reading frame (ORF) was 
inserted into RsrII site. The construct between XhoI sites which contains Tet-CMV 
promoter, 3X Flag tag, JMJD5 ORF and BGH polyadenylation signal was cut out 
from pcDNA5/FRT/TO vector and inserted into pLKO.1 no-stuffer vector (Addgene) 
between XhoI sites. Newly generated plasmids were named as pLTRE-FLAG-
KDM8, pLTRE-FLAG-KDM8H321A and pLTRE-FLAG-empty. 
3.3.3 Cell culture methods 
3.3.3.1 Cell lines and growth conditions of cells 
HepG2-Trex, SNU449-Trex stable cell lines and SNU449-Trex-derived stable 
clones, namely EGEM-W1, EGEM-W2, EGEM-W3, EGEM-W4, EGEM-M1, 
EGEM-M2, EGEM-M3, EGEM-E1, EGEM-M2-C2, EGEM-M2-C4, EGEM-W4-
C2, EGEM-W4-C3, were cultured in complete DMEM or RPMI medium.  
Complete DMEM and RPMI media contained 10 % FBS, 1 % 
penicillin/streptomycin and 1 % non-essential amino acids. The incubation of cells 
was conducted in humidified incubators with 37 C° temperature and 5 % CO2 level. 
Cells were passaged in 2-3 day frequency when the confluency was reached.  
3.3.3.2 Thawing the cells 
Taken from either nitrogen tank or -80 C° freezer, the desired cell lines were 
incubated on ice for a few minutes and thawed at 37 C° in water bath in a few 
minutes. The thawed cell suspension was transferred to a 15 ml falcon tubes and 
mixed with several milliliters of fresh medium, immediately. Cells were spinned 
down at 1500 rpm for 3 min. DMSO was removed together with the supernatant 
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using aspirator. The pellet was resuspended in several milliliters of complete medium 
and transferred to either a 25 cm
2
 flask or 100 mm dish according to the size of the 
pellet. Rocked gently back and forth to evenly distribute the cells, flask or dish was 
incubated in the incubator at 37 C° in 5% CO2 overnight. Next day, dead cells were 
removed and washed with 1X PBS, and the medium was replenished. 
3.3.3.3 Passaging the cells  
Before passaging the cells, the old growth medium was removed by aspiration, and 
the cells were washed with 1X PBS. After the removal of PBS, trypsin-EDTA was 
added onto the cells in dishes or plates. The added volume of the trypsin-EDTA was 
dependent on the surface area of the dish or plate. For example, 500 µl volume was 
added to the 100 mm dishes. The cells were left to incubate in incubators for a few 
minutes until all the cells were detached from the surface. The detached cells were 
mixed thoroughly by adding fresh medium and pipetting up and down with 
serological pipettes. Then, the cells were divided into suitable dishes or flasks with 
desired dilutions. The growth media, trypsin-EDTA and 1X PBS were stored at 4 C°. 
FBS was heat-inactivated at 55 C° for 30 min, filter-sterilized, aliquoted and stored 
at -20 C°. Before use, all media and solutions were warmed up in water bath at 37 
C°.  
3.3.3.4 Cryopreservation of the cells  
After reaching 60-70% confluency, cells were washed with PBS, detached by 
trypsin-EDTA and collected with medium into 15-ml falcon. Cell suspension was 
centrifuged at 1500 rpm for 3 min, and the supernatant was aspired. The cell pellet 
was then resuspended in freezing medium containing 10 % DMSO in complete 
medium. Cells were transferred to the cryotubes, and first stored at -20 C° for 1 hour 
and later at -80 C° overnight. Nitrogen tanks were used for long term storage. 
22 
 
3.3.3.5 Transient transfection of cells using Lipofectamine 2000  
After washing with 1X PBS and trypsinizing, cells were counted on hemocytometer, 
and 6 x 10
5
 cells/well were cultured on 6-well plates in antibiotic-free medium. Cell 
confluency on the plates should be 90-95% after 24h. Preceding transfection, the 
media were aspirated, cells were washed with 1X PBS and 1.5 ml OptiMem I 
Reduced Serum Medium was given into each well. 250 µl/well diluted DNA mix 
was prepared by mixing 4 µg of plasmid of interest per well with OptiMem I 
Reduced Serum Medium. 250 µl/well diluted lipofectamine 2000 mix was prepared 
by mixing 10 µl of lipofectamine 2000 transfection reagent per well with OptiMem I 
Reduced Serum Medium. After gently mixed, the mixtures were incubated for 5 
minutes at room temperature. Diluted DNA and diluted lipofectamine mixtures were 
combined and incubated for 20 minutes at room temperature. 500 µl of complexes 
was divided into each well, completing the volume to 2 ml. The cells were incubated 
in transfection media at 37 C° in 5% CO2 for 4-6 hours. Then, transfection media 
were removed, 2 µg/ml doxycycline (Sigma)-containing complete RPMI 1640 
medium was given to the Dox (+) cells, whereas only complete RPMI was given to 
Dox (-) cells. The cells were incubated at 37 C° in 5% CO2 for 24, 48 and 72 hours.   
3.3.3.6 Stable transfection of cells with lentiviral vectors 
3.3.3.6.1 Production of viral particles 
HEK293T cells were seeded in such a way as to reach 30-40 % confluency in the 
following day, and incubated at 37 C° overnight.  
Transfection mixes (The required amounts per well for 6-well plate transfection are 
shown.) 
Express-In
TM
 (Open Biosystem) Calcium phosphate (CaP) 
Mix A 
TransLenti Viral ORF Packaging  
mix (OpenBiosystem)                    2 µl 
Lentiviral vector                      0,5-1μg 
Optimem                                    500 μl 
Mix A 
TransLenti Viral ORF Packaging  
mix (Open Biosystem)            2 µl 
Lentiviral vector                    0,5-1μg 
CaCl
2
 (1M)                           120 μl 
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Mix B 
Express-In
TM
 (Open Biosystem)   20 μl 
Optimem                                      480 μl  
ddH
2
O                                  360 μl 
Mix B 
2xHBS                                   500 μl 
(In addition to the lentiviral transfection vectors, pLEX JRed TurboGFP vector mix 
was prepared (Evrogen) to check working of transfection in every step of the 
process.) 
A and B mixes were prepared separately and left to wait for 5 minutes. Then two 
mixes were combined and left to wait for 20 minutes at room temperature. 
Completing the volume to 2 ml with complete growth medium, the whole mixtures 
were added to HEK293T cells, and plates were incubated at 37 C° overnight. Next 
day, transfection medium was changed with fresh complete medium.  
3.3.3.6.2 Infection 
The day after the transfection of HEK293T cells, SNU449-TRex cells targeted for 
transfection were seeded on 6-well plates to reach 30-40 % confluency and incubated 
overnight at 37 C°. 48 hours after than HEK293T cell transfection, 2 ml media of 
these cultures which contain viral particles were taken, 8 µg/ml polybrene was 
added, and the media were passed through 42 µm filter. Media of HEK293T cells 
were replenished. The media of target SNU449-TRex cells were removed, and the 
filtered media containing viral particles and polybrene were added to them. Target 
cells were incubated at 37 C° overnight. By collecting the media from HEK293T 
cells every other day, target cells were infected three times in total for efficient 
transfection.  
3.3.3.6.3 Selection 
24 hours after third infection, target SNU449-TRex cells were selected under 9 
µg/ml puromycin concentration, dose being dependent on kill curve of this cell line. 
After 1-week selection, all the control cells were dead, while colonies appeared on 
infected cells.    
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3.3.4 Total protein extraction from cultured cells 
Cells were trypsinized and collected in the pellet. For lysis, cells were mixed up with 
the adequate amount of RIPA buffer by pipetting and vortexing every 5 minutes up 
to 15 minutes. To fragment DNA and increase lysing efficiency, sonication and 3-
minute boiling processes were applied. Cell lysates were centrifuged at 4 C° at 
13,000 rpm for 40 minutes. Supernatants were saved in clean eppendorf tubes, and 
stored at -80 C°.    
3.3.5 Western blotting  
For quantification of protein lysates, Bradford assay was applied. A standard curve 
was drawn with respect to absorbance values of serially diluted BSA proteins of 
known concentrations. The concentrations of sample proteins were calculated by 
putting the absorbance values of them as y values in the standard curve equation. 
Upon mixing with Bradford reagent, a blue- colored complex is formed, giving an 
absorbance maximum at 595 nm on the spectrophotometer. For sample preparation, 
5X SDS loading dye and 5% b-mercaptoethanol in loading dye were added in 
appropriate amounts to 15-30 ug protein lysates, and the volume was completed by 
ddH2O. Denaturation of samples was done at 100 C° for 10-12 minutes.     
All the SDS-PAGE gels and buffers were manually prepared. 12% Tris-glycine gel 
was used for the better resolution of about 50 kD Flag-JMJD5 conjugate protein. 1X 
SDS running and 1X SDS transfer buffers were prepared according to the commonly 
used recipes in the lab. Transfer buffer contained 20 % ethanol, and PVDF 
membrane was used for the transfer. 
Blocking of the obtained membranes was conducted overnight at 4 C° with 5 % BSA 
or milk in 0.3 % TBS-T, according to the suggested protocols for each specific 
antibody. Primary antibody incubation was done for 1 hour at room temperature with 
gentle shaking at certain antibody dilution ratios. Membranes were washed for 5, 15 
and 5 minutes with 0.3 % TBS-T. Membrane was incubated with HRP-conjugated 
secondary antibodies for 1 hour at room temperature with gentle shaking at certain 
antibody dilution ratios. The membrane was additionally washed with TBS-T as in 
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the previous case. Then, for chemiluminescent detection, ECL prime western blot 
detection kit from Thermoscientific was applied according to the manufacturer’s 
protocol. Development of the X-ray films with chemiluminescent emission was 
performed for certain time periods according to the specific antibody.  
3.3.6 Immunofluorescence staining 
SNU449-TRex cells were seeded on sterile coverslips in 12-well plates in 15,000 
cells/well number in order to reach subconfluency on the day of immunoperoxidase 
staining after 3-day culturing.  Doxycycline induction, as being 2 µg/ml, was done in 
the first day of experiment after cells were attached to the surface for 48 hours. Being 
washed with 1X PBS, the cells were both fixed and permeabilized with acetone-
methanol (1:1) mixture at -20 C° for 10 minutes. Then cells were washed with 1X 
PBS three times for 5 minutes each. Blocking was applied with 10 % FBS, 0.3 % 
Triton X-100 in 1X PBS for 1 hour at 37 C°. Primary antibody was diluted in a 
buffer containing 1 % BSA, 0.3 % Triton X-100 in 1X PBS depending on the 
specific antibody and applied directly onto the coverslips drop by drop. The 
coverslips were incubated at 37 C° for 2 hours. Then cells were washed three times 
with 0.3 % 1X PBS-T for 5 minutes each and incubated with fluorescent dye-
conjugated secondary antibody for 1 hour at room temperature in dark. Washing of 
the secondary antibody was performed similar to the primary antibody. DAPI 
counterstaining was performed by diluting 1/10,000 in ddH2O and applying for 3 
minutes at room temperature. The excessive counterstain was removed by ddH2O 
washing, and mounting of coverslips onto the slides was done with DAKO mounting 
medium. Fluorescent microscope (ZEISS) was used to examine the samples.                
3.3.7 Immunoperoxidase staining 
SNU449-TRex cells were seeded on sterile coverslips in 6-well plates in 15,000 
cells/well number in order to reach subconfluency on the day of immunoperoxidase 
staining after 3-day culturing.  Doxycycline induction, as being 2 µg/ml, was done in 
the first day of experiment after cells were attached to the surface for 48 hours. Being 
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washed with 1X PBS, the cells were both fixed and permeabilized with acetone-
methanol (1:1) mixture at -20 C° for 10 minutes. Then cells were washed with 1X 
PBS three times for 5 minutes each. To stop endogenous peroxidase activity, 
hydrogen peroxide was added to each well and incubated for 10 minutes at room 
temperature in dark. The cells were again washed with 1X PBS three times for 5 
minutes each. Blocking was applied with 10 % FBS, 0.3 % Triton X-100 in 1X PBS 
for 1 hour at room temperature. Primary antibody was diluted in blocking solution 
depending on the specific antibody and applied directly onto the coverslips. The 
coverslips were incubated at 37 C° for 2 hours. Then cells were washed twice with 
0.3 % 1X PBS-T for 2 minutes each and incubated with secondary antibody (DAKO, 
anti-mouse and anti-rabbit together) for 1 hour at room temperature in dark. Washing 
of the secondary antibody was performed similar to the primary antibody. DAKO-
DAB Chromogen solution was prepared according to the manufacturer’s protocol, 
added onto only one coverslip as drops, left to wait until reaction occurs and gives 
brown-colored product, and time was recorded. Then each well was treated with this 
substrate for determined amount of time. After reaction was stopped with ddH2O, 
Haemotoxylin (Mayer’s, Sigma) counterstaining was performed for 3-5 minutes. The 
excessive counterstain was removed by ddH2O washing, and mounting of coverslips 
onto the slides was done with DAKO mounting medium. Light microscope (ZEISS) 
was used to examine the samples. 
3.3.8 Bromodeoxyuridine (BrdU) and Flag double immunofluorescence 
staining 
SNU449-TRex clones were seeded on 12-well plates in 30,000 cells/well density, 
and fresh medium containing both doxycycline and BrdU was given to all cells. 
After 4-hour incubation, all medium was removed. The medium with doxycycline 
but without BrdU was added, and cells were incubated in this medium for 48 hours. 
Following fixation in 70 % ice-cold ethanol at -20 C° for 10 minutes, cells were 
washed with 1X PBS three times for 5 minutes each. Blocking was applied with 10 
% FBS, 0.3 % Triton X-100 in 1X PBS for 1 hour at 37 C°. Primary Flag polyclonal 
antibody (Rb) was diluted in a buffer containing 1 % BSA, 0.3 % Triton X-100 in 1X 
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PBS depending on its working dilution ratio and applied directly onto the coverslips 
drop by drop. The coverslips were incubated at 37 C° for 2 hours. Then cells were 
washed three times with 0.3 % 1X PBS-T for 5 minutes each. Alexa 568-conjugated 
anti-Rabbit secondary antibody was applied in its specific dilution ratio at room 
temperature for 1 hour, and three times washing with 0.3 % 1X PBS-T was done. 
Then fixation was repeated with 70 % ice-cold ethanol at -20 C° for 10 minutes in 
order to keep Flag primary and secondary antibodies attached to their targets. 2 N 
HCl treatment for 30 minutes at 37 C° was applied to denature double stranded DNA 
structure. Neutralization was carried out with borate buffer, and cells were washed 
with 1X PBS three times. BrdU primary antibody treatment was applied at 37 C° for 
1 hour and followed by PBS-T washes three times. Alexa 488-conjugated anti-mouse 
secondary antibody incubation was performed at room temperature for 1 hour, and it 
was washed with PBS-T three times. DAPI counterstaining was performed by 
diluting 1/10,000 in ddH2O and applying for 3 minutes at room temperature. The 
excessive counterstain was removed by ddH2O washing, and mounting of coverslips 
onto the slides was done with DAKO mounting medium. Fluorescent microscope 
(ZEISS) was used to examine the samples. 
3.3.9 Flow cytometry analysis of JMJD5 - expressing clones 
Being treated with doxycycline as previously mentioned, cells were rinsed with 1X 
PBS, trypsinized and divided into 15 ml falcons. Then cells were centrifuged at 1500 
rpm for 5 minutes. Pellets were resuspended in 70 % PBS-ice cold ethanol, and tubes 
were incubated at -20 C° for 15 minutes for fixation and permeabilization. Cells were 
centrifuged at 1800 rpm for 8 minutes, PBS-ethanol solution was removed, and 
pellets were washed with 1X PBS. Primary antibody solution was prepared in 0.1 % 
PBS-T, being 1:200 dilution for Sigma mouse M2 monoclonal anti-flag antibody. 
The pellets were resuspended in 100 µl of primary antibody solution and incubated at 
room temperature for 1 hour with a few-time vortexing. Mouse IgG1-FITC isotype 
control was applied as being 4 µl in 100 µl of 0.1 % PBS-T and incubated in the 
same manner. After 1X PBS-T wash, Sigma FITC-conjugated anti-mouse secondary 
antibody, being properly diluted in 0.1 % PBS-T, was applied to the cells for 30 
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minutes in the dark with gentle agitation. After 1X PBS-T wash, for DNA staining, 
cells were incubated at 37 C° for 30 minutes in 500 µl propidium iodide buffer 
containing 50 µg/ml Sigma propidium iodide, 0.1 mg/ml Thermoscientific RNase A 
and 0.5 % Triton X-100. After cells were washed twice with 1X PBS and 
resuspended in appropriate amount of PBS, cell cycle analysis was performed using 
BD Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA) and BD Accuri C6 
CFlow Sampler software. 
3.3.10 RNA sample preparation and hybridization to chip  
Total RNA isolation from triplicate samples of empty and wild type JMJD5 clones 
was performed with Nucleospin RNA kit (MN, Düren, Germany) according to the 
manufacturer’s protocol. RNA quality was checked using Agilent Bioanalyzer 2100 
kit and software (Agilent Technologies, Santa Clara, CA, USA) according to the 
manufacturer’s protocol. RNA isolates were hybridized to Affymetrix 
HG_U133_Plus2 chips, applying Affymetrix 3’ IVT hybridization protocol in 
Bilkent University Bilgen Affymetrix Center for microarray analysis.      
3.3.11 Bioinformatics data analyses of JMJD5 microarray samples 
Heatmap of JMJD5 probe set (Figure 4.2) was generated using the publically 
available microarray dataset (GSE6765) [38] downloaded from the gene expression 
omnibus website. The dataset was normalized using the RMA normalization method. 
Heatmap was generated using Cluster 3.0 software [39] and Java TreeView software 
[40].  
Microarray raw files of three replicates of empty vector over-expression samples 
(EGEM_e1a, EGEM_e1b, and EGEM_e1c) and three replicates of wild type (wt) 
JMJD5 over-expression samples (EGEM_w4a, EGEM_w4b, and EGEM_w4c) were 
normalized with the RMA method using the BRB_Array_Tools Version 4.2.0 
developed by Dr. Richard Simon and BRB-ArrayTools Development Team. Class 
comparison tool of the BRB_Array_Tools program was used to determine the list of 
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significantly (>1.5 fold and p<0.05) differentially expressed genes between empty 
vector and wt JMJD5 samples.  
In order to determine differing biological mechanisms as a result of over-expression 
of JMJD5 in SNU449 cells, gene set enrichment analysis (GSEA) experiments were 
performed using normalized microarray data together with C5_ALL gene ontology 
gene sets or C6_ALL oncogenic signatures curated gene lists of molecular signature 
databases (MSigDB). 
3.3.12 Sulphordamine B (SRB) assay for cell proliferation 
EGEM-w2, EGEM-w4, EGEM-m2, EGEM-m3 and EGEM-e1 clones were seeded 
on 96-well plates in 2000 cells/well density in triplicates for both Dox (+) and Dox (-
) conditions. All the outer wells were filled with 200 µl PBS. Next day, fresh 
medium containing doxycycline was added to Dox (+) wells, completing the volume 
in each well to 300 µl and letting the final doxycycline concentration be 2 µg/ml. 
Cells were cultured for 6 days, replenishing doxycycline from top of the wells every 
2 days. Upon reaching the over-confluency, cells were taken out for SRB fixation 
and staining protocol. The media were discarded very gently, and wells were washed 
slowly with 200 µl 1X PBS. Fixation was done with 10 % TCA for 1 hour at +4 C° 
for 1 hour in dark. Cells were washed 4-5 times with dH2O, and plates were allowed 
to dry overnight on the bench. 0.4 % SRB solution was prepared by dissolving SRB 
powder in 1 % acetic acid and applied to the wells as 50 µl/well at room temperature 
for 20 minutes in dark. After discarding the dye, the plates were washed five times 
with 1 % acetic acid on plate washer device (BioTek). The plates were left to dry in 
fume hood for 1 hour, and then they were scanned. 10 mM pH 10.5 cold Tris base 
from + 4 C° was added into each well, and dye was dissolved by shaking 10 seconds 
on plate shaker. OD values were then read on Elisa reader (BioTek) at 515 nm 
primary wavelength, using KC Calbiochem program.  
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3.3.13 SRB assay for Adriamycin resistance 
SNU449 TRex, EGEM w4-C2, EGEM w4-C3, EGEM m2-C2, EGEM m2-C4 and 
EGEM-e1 clones were seeded on 96-well plates in 5000 cells/well density in 
triplicates. All the outer wells were filled with 200 µl PBS. Next day, medium 
containing 2X adriamycin and doxycycline was added to all wells, completing the 
volume in each well to 200 µl and letting the final doxycycline concentration be 2 
µg/ml. Adriamycin concentration range was arranged between 10 µg/ml and 0. The 
cells were incubated for 72 hours, and SRB staining protocol was performed as 
explained above. 
3.3.14 Wound healing assay 
Cells were seeded on 6-well plates as 4 x 10
5
 cells/well in complete RPMI medium. 
Next day, wounding was done with FT200 pipette. Cells were washed with 1X PBS 
twice. Complete RPMI medium containing 2 µg/ml doxycycline was given to the 
cells. Cells were incubated at 37 °C, 5 % CO2 for 48 hours. Photos were taken at 0, 
24 and 48 hours using the inverted light microscope. 48 hour- cultured cells were 
then fixed with acetone-methanol (1:1) at -20 °C for 10 minutes and washed with 1X 
PBS three times. Staining with 1 % cystal violet in 2 % ethanol was performed for 30 
minutes at room temperature in dark. Following washing with ddH2O several times, 
the photos of the stained cells were taken again. 
3.3.15 Soft agar colony formation assay 
3.3.15.1 Preparation of base agar 
All the glassware, materials and water were sterile. 1 % agar solution was prepared 
by dissolving in water heating with microwave and cooled to 40 °C in a water bath. 
2X DMEM medium, prepared from its powder form adding the missing components 
according to its datasheet, with 20 % FBS, 2 % penicillin-streptomycin and 2 % non-
essential amino acids was left to wait with 1 % agar solution in the water bath for 
about 30 minutes to equilibrate them. Two solutions were mixed in equal volumes in 
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order to obtain 0.5 % agar in 1X DMEM, 10 % FBS, 1 % penicillin-streptomycin 
and 1 % non-essential amino acids. 1 ml of the mixture was put into each well of 6-
well plates and allowed to wait for 5 minutes for solidification of agar.  
3.3.15.2 Preparation of top agar 
0.7 % agar solution was prepared in water and left to equilibrate with 2X DMEM 
containing 20 % FBS, 2 % penicillin-streptomycin and 2 % non-essential amino 
acids in water bath, as described above. Adherent cells were trypsinized and counted. 
They were divided into 15-ml falcon tubes in such a way as to obtain 10,000 cells in 
100 µl volume of medium per each falcon tube. 6-well plates were labeled properly. 
2 ml of 2X DMEM containing 20 % FBS, 2 % penicillin-streptomycin and 2 % non-
essential amino acids; and 2 ml of 0.7 % agar were added to a tube of cells, mixed 
and divided as 1 ml/well into 6-well plates. Only one tube at a time was performed 
not to allow agar to solidify early. Plates were incubated at 37 C° in a humidified 
incubator for 3-4 weeks. Agar media were feeded with 1 ml complete culture 
medium containing 2 µg/ml doxycycline. The colonies were counted, and their 
photos were taken under inverted light microscope. 
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CHAPTER 4 
RESULTS 
4.1 JMJD5 
4.1.1 Knowledge about JMJD5 on NCBI 
Jumonji domain containing 5 (JMJD5), also known as KDM8, is a protein coding 
gene located in chromosome 16 at 16p12.1 locus in the neighborhood of NSMCE1, 
FLJ21408 and EEF1A1P38, genes. Existing bioinformatics information about 
JMJD5 obtained from NCBI and PROSITE web tools are illustrated in Figure 4.1.      
 
Figure 4.1: Genomic location, transcript variants and conserved domains of JMJD5 isoforms  
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Two transcript variants are present in humans for this gene. The lengths of variant 1 
and 2 are 2531 bp and 2481 bp, encoding 454-amino acid and 416-amino acid long 
isoform 1 and 2, respectively. The molecular weights of isoform 1 and 2 are 51 kD 
and 47 kD, respectively. Splice variant 1 has 8 exons, all of which encode the 
isoform 1. Splice variant 2 has also 8 exons, 7 of which encode isoform 2, translation 
being started from an alternative exon at downstream. Conserved domain search 
indicates that both isoforms have catalytic JmjC domain at C-terminus.  
4.2 Expression Levels of JMJD5 in Healthy-Diseased Liver and 
HCC Cell Lines   
4.2.1 In Vivo JMJD5 Expression 
Alteration of JMJD5 mRNA and protein levels between different stages of liver 
disease was determined by our lab members in previous studies. Microarray analysis 
of liver samples corresponding to 8 different states of liver disease for JMJD5 
expression is demonstrated in Figure 4.2. 
 
Figure 4.2: Microarray data of different liver conditions for JMJD5 levels  
(Red indicates upregulation, and green indicates downregulation of the gene.) 
According to the figure, there is a drastic decrease in JMJD5 expression from normal 
liver toward very advanced HCC, the intermediate stages also exhibiting the gradual 
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change with the color designation. From normal liver to dysplasia, the color turns 
from red to black in most cases; and from dysplasia to very advanced HCC, black 
color turns into light green, showing how sharply this change occurs between the 
stages as HCC progresses.  
This tendency was also checked in protein levels with western blotting using samples 
from Dokuz Eylül University, İzmir (collaboration with Dr. Esra Erdal). Cirrhotic 
and HCC liver tissue samples from same individual patient were taken, making up 15 
patients and 30 tissue samples in total. All samples were analyzed with JMJD5 
polyclonal antibody in Figure 4.3 (Eylül Harputlugil and Mehmet Öztürk, personal 
communication).   
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Figure 4.3: Screening for JMJD5 expression in HCC and cirrhosis sample pairs of 15 patients 
using western blotting technique  
(P: patient; Calnexin for equal loading; rat liver and 49-TK-HCC are for positive control. Rat liver 
indicates 47 kD rat JMJD5 isoform 2; whereas 49-TK-HCC indicates both 51 and 47 kD human 
JMJD5 isoforms.) 
In all of the samples 51-kD isoform 1 is visible. 47-kD isoform 2 is also seen in most 
of the samples with a few exceptions. Levels of both isoforms exhibited oscillations 
between HCC and cirrhotic samples of the same patient. JMJD5 isoform 1 levels 
decreased in HCC samples of 7 patients compared to their cirrhotic samples, 
remaining at comparable levels in 5 patients and showing an increase in 3 of them. 
JMJD5 isoform 2 levels, on the other hand, decreased in HCC samples of 10 patients 
compared to their cirrhotic samples, remaining at comparable levels in 3 patients and 
showing an increase in 2 of them. In majority of the cases, both isoforms were 
downregulated from cirrhosis to HCC. This result seems to be consistent with the 
previous microarray data in that the fall in JMJD5 expression might be critical in 
progression of cirrhosis to carcinoma. These results collectively suggest the possible 
tumor suppressor role of JMJD5 in normal liver and early phases of liver injury, its 
gradual decrease contributing to the development of cancer.  
4.2.2 In Vitro JMJD5 Expression 
In addition to these in vivo data, JMJD5 expression in HCC cell lines was also tested 
using qRT-PCR (Gökhan Yıldız and Mehmet Öztürk, personal communication).   
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Figure 4.4: Fold change of JMJD5 expression in HCC cell lines  
In Figure 4.4, fold change values indicate that JMJD5 expression in RNA levels 
decreases from epithelial-like HCC cell lines to mesenchymal-like HCC cell lines 
dramatically. This result shows that JMJD5 levels are drastically reduced as HCC 
becomes more advanced, suggesting the tumor suppression role for JMJD5 similar to 
the in vivo data.  
In order to study overexpression of a gene of interest, basal levels of that gene should 
be relatively low in a cell type. If the expression is considerably high, the 
overexpression does not make very much sense in terms of the phenotype. Consistent 
with this phenomenon, mesenchymal-like cells seem to be suitable for 
overexpression analysis. Hence, SNU449 cells with highly low JMJD5 expression 
were used in this study as a model HCC cell line.        
4.3 Maps of JMJD5 Plasmids and Restriction Enzyme Digestion 
Control  
Tumor suppressor role of JMJD5 in liver cancer was investigated using a 
mesenchymal-like cell line model SNU449, which was derived from a patient with 
advanced-(grade II-III/IV) HCC [41]. Overexpression of JMJD5 in SNU449 cells 
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through its stable transfection by lentiviral vectors was planned to test JMJD5’s 
effects on phenotype or tumor growth of this HCC cell line. SNU449-TRex clone 
derived from this cell line by Hani Alotaibi and Pelin Telkoparan (personal 
communication), which expresses Tet repressor protein, was used for the regulated 
expression of JMJD5. Tet-ON expression system derived from pcDNA5/FRT/TO 
plasmid was cloned into pLKO.1 puro vector as explained in the methods section to 
provide inducible JMJD5 expression by working in compatibility with SNU449- 
TRex cells. Figure 4.5 shows the created map of pLTRE plasmids which contain 
JMJD5 constructs. 
 
Figure 4.5: Map of pLTRE-FLAG-KDM8 plasmid  
(“A Plasmid Editor” (ApE) programme was used to create this map.)  
Puromycin and ampicillin resistance markers are required for selection in 
mammalian and bacterial cells, respectively. 5’ and 3’ long terminal repeats (LTRs) 
enable the lentiviral DNA to be integrated into host genome.  
38 
 
The cloning of the construct occurred in the reverse direction; hence, JMJD5 is 
expressed in counterclockwise direction according to this map. This map illustrates 
the wild type JMJD5 ORF. The 3-bp mutation site in JmjC domain of JMJD5 is also 
demonstrated in yellow color. Those 3 basepairs only were changed to create the 
map of pLTRE-FLAG-KDM8H321A plasmid. The map of pLTRE-FLAG-empty 
plasmid was also created by deleting JMJD5 ORF between RsrII sites.  
The correctness of these plasmid maps was tested by restriction enzyme digestion 
with NcoI as depicted in Figure 4.6.    
 
Figure 4.6: NcoI restriction enzyme digestion results for JMJD5 plasmids on 1 % agarose gel  
(GeneRuler
TM
 DNA ladder mix is shown on the right. The expected band sizes after digestion of each 
plasmid are shown at the bottom of the figure and were obtained using ApE. Each plasmid was 
analyzed in duplicates.) 
The expected band sizes after digestion of wild type and mutant plasmids were 5542 
bp, 2155 bp, 599 bp and 396 bp; whereas those of empty plasmid were 4883 bp, 
2155 bp and 396 bp. As compared to the migration of DNA ladder bands on the gel, 
all restriction digestion products seemed to give the correct bands of expected sizes. 
This result confirmed the maps and contents of the pLTRE plasmids. 
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4.4 Transient Exogenous JMJD5 Expression in SNU449-TRex Cells 
4.4.1 Tet-ON Inducible Transient Expression of Exogenous JMJD5 at 24 and 
48 Hours 
To check whether Tet-ON system of pLTRE plasmids works or not in SNU449-
TRex cells, transient transfection with the constructs and western blot detection were 
applied.  
 
Figure 4.7: Flag-JMJD5 recombinant protein expression upon 24 h and 48 h doxycycline 
induction in SNU449-TRex cells transiently transfected with wild type and mutant constructs of 
JMJD5 gene  
(WT: wild type, Mut: mutant, Un: untransfected, Dox: doxycycline) 
Total protein lysates of the cells were run on SDS-PAGE gel, and N terminally-
tagged JMJD5 protein was detected with Flag monoclonal antibody. Molecular 
weight of Flag-JMJD5 protein is about 50 kD. As seen in Figure 4.7, this band is 
obtained slightly below the 55 kD band of the ladder. The fact that untransfected 
cells do not contain this band also confirms the specificity of the antibody to the 
protein of interest. Contrary to the expectation, there are remarkable bands in Dox (-) 
cells, indicating that the expression cannot be repressed under Dox (-) condition, and 
there is a substantial amount of leaky expression. At 24 hour doxycycline induction, 
the expression does not seem to be inducible, while at 48 hour induction, there is a 
slightly noticeable induction as indicated by the relatively more intense bands in Dox 
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(+) cells than Dox (-) cells. This result suggests that JMJD5 is exogenously 
expressed in SNU449-TRex cells, and Tet-ON inducible system seems to work better 
under 48 hour doxycycline induction despite the presence of great leaky expression.   
4.4.2 Tet-ON Inducible Transient Expression of Exogenous JMJD5 at 48 
Hours 
Since Figure 4.7 suggests that the inducible expression occurs at 48 hours, transient 
transfection followed by western blot detection was tested again only for 48 hour 
doxycycline induction in a separate experiment using the same antibody.  
  
Figure 4.8: Flag-JMJD5 recombinant protein expression upon 48 h doxycycline induction in 
SNU449-TRex cells transiently transfected with wild type and mutant constructs of JMJD5 gene  
(WT: wild type, Mut: mutant, Un: untransfected, Dox: doxycycline) 
As indicated in Figure 4.8, the desired Flag-JMJD5 band is obtained around 50 kD 
size. Although leaky expression is still observed under no induction, the band 
intensities in Dox (+) wild type and mutant transfectants are much higher than those 
in Dox (-) cells. This result confirms that both wild type and mutant constructs of 
JMJD5 are expressed in an inducible manner at 48 hours when introduced into 
SNU449-TRex cells in a Tet-ON expression plasmid.  
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4.5 Determining the Optimum Drug Concentrations for Selection 
of Stable Colonies Using Kill Curve Method 
Since pLTRE plasmid contains puromycin selective marker, cells stably transfected 
with these constructs are resistant to puromycin antibiotic to a certain extent. In very 
high doses of puromycin, even the stable cells cannot survive, or in low doses, even 
untransfected cells can survive. Therefore, an optimum drug concentration is 
required in culture medium in order to eliminate the untransfected cells but to keep 
transfected ones in a healthy and proliferating state. This concentration was 
determined using the method so-called “kill curve”. 
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Figure 4.9: Commassie Brilliant Blue staining of untransfected SNU449-TRex cells incubated in 
different concentrations of puromycin for 6 days  
(The duplicate images represent an average view of the plates and were taken at 10X.)    
As shown in Figure 4.9, the puromycin dose sufficient to kill about all the 
untransfected SNU449-TRex cells at day 6, which was 9 µg/ml, was assigned to be 
the optimum dose. Stable lentiviral transfectants were selected under this puromycin 
concentration. For culture and growth of the stable clones, a lower dose of 
puromycin, 6 µg/ml, was used. As previously determined by Hani Alotaibi and Pelin 
Telkoparan for SNU449-TRex cells, 2 µg/ml blasticidin was also added to the 
selective growth media of the stable clones. 
4.6 Tet-ON Inducible Exogenous JMJD5 Expression in Stable 
Clones 
4.6.1 Western Blot Analysis 
Stable JMJD5-expressing polyclonal cell populations were created by lentiviral 
transduction and antibiotic selection (Emre Yurdusev and Mehmet Öztürk, personal 
communication).  We then tested these cells for inducible JMJD5 expression using 
Flag monoclonal antibody. In Figure 4.10, western blot analysis for the tested clones 
is illustrated. Similar to the transient expression experiments, the cells were induced 
with 2 µg/ml doxycycline for 48 hours.    
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Figure 4.10: Inducible JMJD5 expression in stable clones  
(EGEM: Engin-Gokhan-Emre-Mehmet, w: wild type, m: mutant, e: empty, Dox: doxycycline)     
As shown in Figure 4.10, the desired Flag-JMJD5 band is observed around 50 kD in 
all wild type and mutant clones. Since there is no specific protein for Flag antibody 
binding, no band could be seen in empty clone as expected. The leakage in the Tet-
ON system is still present at a considerable level in Dox (-) cells, being quite lower 
than in transient transfection case. Upon doxycycline induction, the increase in the 
expression is much clearer in all wild type and mutant clones. This result indicates 
that the analyzed stable clones are positive for exogenous JMJD5, and the expression 
is inducible. 
4.6.2 Immunofluorescence Analysis 
Immunoflorescence staining of stable clones were also performed using flag 
monoclonal antibody after 48-hour doxycycline induction.  
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Figure 4.11: Immunoflorescence staining of stable clones for exogenous JMJD5  
(The images were taken at 20X. DAPI stains nucleus (blue), and Alexa 488 stains Flag-JMJD5 
(green).)                                      
According to Figure 4.11, exogenous Flag-JMJD5 expression is detectable in all wild 
type and mutant clones, but the percentage positivity changes between clones. The 
leaky expression is present, and doxycycline induction is not so dramatic. JMJD5 
positivity percentage for each clone was calculated by counting green Alexa signals 
and blue DAPI signals in triplicate random areas as indicated in Table 4.1.      
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Table 4.1: JMJD5 positivity for each clone  
(Triplicate random areas were counted. The marked clones with relatively higher positivity and 
induction were selected for further phenotypic analyses.) 
 
According to Table 4.1, the positivity of stable clones is not 100 %, maximally 
reaching up to 47 % in EGEM-m2. The leakiness is also remarkably high, even 
reaching up to 29 % in EGEM-w3. The mild doxycycline induction in the clones is 
also quantitatively detected. What is concluded from immunoflorescence staining 
and counting result is that JMJD5 positivity of the clones is not homogenous, quite 
low, even not reaching to 50 %, and the induction is weak. 
4.7 Comparison of Genome-wide Expression Profiles between 
EGEM-w4 and EGEM-e1 
Microarray expression profiles of EGEM-w4 and EGEM-e1 were compared to shed 
light on target genes and target pathways of JMJD5 and to reveal its association with 
liver carcinoma. For this purpose, two types of analyses were made. In the first one, 
the genes that change significantly between empty and wild type clones were 
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determined and listed. In the second one, gene sets were analyzed in terms of cellular 
pathways or oncogenic properties to find out a relationship between JMJD5 and a set 
of genes with a similar property.  
4.7.1 Altered Genes 
The genes with at least 1.5 fold significant expression change in EGEM-w4 relative 
to EGEM-e1were listed in Table 4.2 and 4.3.  
Table 4.2: 26 genes at least 1.5 fold upregulated with significance level of 0.05 in EGEM-w4 
clone compared to EGEM-e1 clone  
(Fold change is the ratio of the expression level in EGEM-e1 to that in EGEM-w4. Two microarray 
probesets that did not match with a known gene were not shown.)     
Gene  Fold ratio 
(control/
Wt-
JMJD5 
Name Defined Genelist 
ASZ1  0.39 ankyrin repeat, SAM 
and basic leucine 
zipper domain 
containing 1 
  
ENPP2 0.41 ectonucleotide 
pyrophosphatase/phosp
hodiesterase 2 
Nicotinate and nicotinamide metabolism, 
Pantothenate and CoA biosynthesis, Purine 
metabolism, Riboflavin metabolism, Starch 
and sucrose metabolism 
FAM198
B  
0.48 family with sequence 
similarity 198, member 
B 
  
EMP3 0.49 epithelial membrane 
protein 3 
  
LOC283
104 
0.53 hypothetical 
LOC283104 
  
FAM84B  0.53 family with sequence 
similarity 84, member 
B 
  
ALDH1
A1  
0.58 aldehyde 
dehydrogenase 1 
Retinol metabolism 
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family, member A1 
DEPTO
R  
0.6 DEP domain 
containing MTOR-
interacting protein 
  
TPD52L
1  
0.6 tumor protein D52-like 
1 
  
RDH10  0.6 retinol dehydrogenase 
10 (all-trans) 
  
FABP5 0.61 fatty acid binding 
protein 5 (psoriasis-
associated) 
PPAR signaling pathway 
FAP 0.62 fibroblast activation 
protein, alpha 
angiogenesis, cell_cycle, cell_signaling, 
metastasis 
TPD52L
1  
0.62 tumor protein D52-like 
1 
  
IL7  0.62 interleukin 7 
 
Cytokines and Inflammatory Response, IL-7 
Signal Transduction, Regulation of 
hematopoiesis by cytokines, Cytokine-
cytokine receptor interaction, Hematopoietic 
cell lineage, Jak-STAT signaling pathway, 
immunology 
OLFML
2A 
0.62 olfactomedin-like 2A   
TNFAIP
6  
0.63 tumor necrosis factor, 
alpha-induced protein 6 
immunology 
TSPAN7  0.63 tetraspanin 7   
WNT5A  0.64 wingless-type MMTV 
integration site family, 
member 5A 
Perou's- Intrinsic- Breast-Cancer-Genes, 
Hedgehog signaling pathway, Wnt signaling 
pathway, development, tsonc 
RDH10  0.65 retinol dehydrogenase 
10 (all-trans) 
  
MALL  0.65 mal, T-cell 
differentiation protein-
like 
immunology 
TNFAIP
6  
0.65 tumor necrosis factor, 
alpha-induced protein 6 
immunology 
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ERBB3 0.65 v-erb-b2 erythroblastic 
leukemia viral 
oncogene homolog 3 
(avian) 
Neuroregulin receptor degredation protein-1 
Controls ErbB3 receptor recycling, Role of 
ERBB2 in Signal Transduction and Oncology, 
Calcium signaling pathway, cell_cycle, 
cell_signaling, signal_transduction, tsonc 
THBS2 0.66 thrombospondin 2 Cell Communication, ECM-receptor 
interaction, Focal adhesion, TGF-beta 
signaling pathway, angiogenesis, immunology 
PEG10 0.66 paternally expressed 10   
POPDC3 0.66 popeye domain 
containing 3 
  
BHLHE4
1  
0.67 basic helix-loop-helix 
family, member e41 
Circadian rhythm 
 
According to the upregulated gene list in Table 4.2, 26 genes seem to be upregulated 
under JMJD5 overexpression, not meaning that all of them are JMJD5 targets. The 
diversity of biological roles played by these genes makes a logical guess about 
function of JMJD5 even more difficult. However, most of the overexpressed genes 
are related with immunology and cytokines, implying a possible involvement of 
JMJD5 in immune regulatory processes through expression of cytokines. 
Angiogenesis and cell cycle were the second most common biological roles of the 
upregulated genes. Some of the genes were also associated with retinol metabolism. 
On the other hand, as shown in Table 4.3, 37 genes were detected to be 
downregulated in EGEM-w4. Most of these genes were associated with lipid, sugar 
metabolism and biosynthesis of several organic molecules. Many of the genes were 
also related to immunology, again pointing to the possible immune function of 
JMJD5. A few members related to phospholipase C and calcium signaling pathways 
were also observed.     
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Table 4.3: 37 genes at least 1.5 fold downregulated with significance level of 0.05 in EGEM-w4 
clone compared to EGEM-e1 clone  
(Fold change is the ratio of the expression level in EGEM-e1 to that in EGEM-w4. Four microarray 
probesets that did not match with a known gene were not shown.)  
Gene Fold Name Defined Genelist 
DIS3L2  1,51 DIS3 mitotic control homolog 
(S. cerevisiae)-like 2 
  
BCHE  1,51 butyrylcholinesterase immunology, pharmacology 
C7orf58  1,51 chromosome 7 open reading 
frame 58 
  
MYO5B  1,52 myosin VB   
LIMCH1  1,52 LIM and calponin homology 
domains 1 
  
ABHD5  1,52 abhydrolase domain 
containing 5 
  
TBC1D2  1,53 TBC1 domain family, member 
2 
  
PPM1E 1,54 protein phosphatase, 
Mg2+/Mn2+ dependent, 1E 
  
UPK1B 1,54 uroplakin 1B immunology 
KLHL5  1,54 kelch-like 5 (Drosophila)   
GAS6  1,56 growth arrest-specific 6 immunology 
CDH4  1,57 cadherin 4, type 1, R-cadherin 
(retinal) 
Cell adhesion molecules (CAMs), 
cell_signaling, metastasis 
CDH4  1,57 cadherin 4, type 1, R-cadherin 
(retinal) 
Cell adhesion molecules (CAMs), 
cell_signaling, metastasis 
C7orf58  1,58 chromosome 7 open reading 
frame 58 
  
ITM2A 1,58 integral membrane protein 2A   
SFRP1  1,6 secreted frizzled-related 
protein 1 
Wnt signaling pathway, development 
UACA 1,61 uveal autoantigen with coiled-
coil domains and ankyrin 
repeats 
  
PLCE1  1,62 phospholipase C, epsilon 1 Phospholipase C-epsilon pathway, 
Calcium signaling pathway, Inositol 
phosphate metabolism, 
Phosphatidylinositol signaling system 
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TMEM45A 1,62 transmembrane protein 45A   
EPS8L2  1,63 EPS8-like 2   
FANCA 1,63 Fanconi anemia, 
complementation group A 
BRCA1-dependent Ub-ligase activity, 
Role of BRCA1, BRCA2 and ATR in 
Cancer Susceptibility, DNA_damage, 
immunology 
TMEM27 1,65 transmembrane protein 27   
FA2H 1,7 fatty acid 2-hydroxylase   
CCL2  1,71 chemokine (C-C motif) ligand 
2 
Low-density lipoprotein (LDL) 
pathway during atherogenesis, 
Msp/Ron Receptor Signaling Pathway, 
Pertussis toxin-insensitive CCR5 
Signaling in Macrophage, Cytokine-
cytokine receptor interaction 
DPYSL3  1,75 dihydropyrimidinase-like 3   
ST6GALNAC5  1,75 ST6 (alpha-N-acetyl-
neuraminyl-2,3-beta-
galactosyl-1,3)-N-
acetylgalactosaminide alpha-
2,6-sialyltransferase 5 
Glycan structures - biosynthesis 2, 
Glycosphingolipid biosynthesis - 
ganglioseries 
ADRB2  1,82 adrenergic, beta-2-, receptor, 
surface 
Corticosteroids and cardioprotection, 
Cystic fibrosis transmembrane 
conductance regulator (CFTR) and 
beta 2 adrenergic receptor (b2AR) 
pathway, Phospholipase C-epsilon 
pathway, Calcium signaling pathway, 
Neuroactive ligand-receptor 
interaction, behavior, immunology 
ITM2A 1,83 integral membrane protein 2A   
PLCE1  1,85 phospholipase C, epsilon 1 Phospholipase C-epsilon pathway, 
Calcium signaling pathway, Inositol 
phosphate metabolism, 
Phosphatidylinositol signaling system 
GREM1  1,89 gremlin 1   
GREM1  1,92 gremlin 1   
SPP1 1,95 secreted phosphoprotein 1 Regulators of Bone Mineralization, 
Cell Communication, ECM-receptor 
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interaction, Focal adhesion, 
immunology 
FOXF2  2,13 forkhead box F2   
NNMT  2,18 nicotinamide N-
methyltransferase 
Nicotinate and nicotinamide 
metabolism, immunology 
IGFN1  2,69 immunoglobulin-like and 
fibronectin type III domain 
containing 1 
  
CHRDL1  2,72 chordin-like 1   
SPOCK1  4,58 sparc/osteonectin, cwcv and 
kazal-like domains 
proteoglycan (testican) 1 
  
4.7.2 Altered Gene Sets 
Gene set enrichment analysis results are indicated in Table 4.4. Each gene set 
contains a certain number of cells involved in the same biological process. When the 
results are analyzed in detail, it is seen that highly diverse cellular pathways are 
upregulated in both clones. Particularly, in wild type cells, most of the enriched gene 
sets are related to metabolic processes and normal cellular processes, only one being 
directly related to cell proliferation. That was the gene set of G2-M transition of 
mitotic cell cycle. Interestingly, the gene set responsible for positive regulation of 
angiogenesis was enriched in EGEM-w4, as also observed in the case of single 
genes. This could be one suspected cellular process potentially regulated with the 
participation of JMJD5. On the other hand, in EGEM-e1 cells, several gene sets seem 
to be directly related to cell growth and proliferation, such as G1 phase of mitotic 
cell cycle, helicase activity, regulation of growth, DNA replication, etc. Accordingly, 
it seems that many abnormal growth pathways are active in empty cells, but the 
number of them is greatly reduced in JMJD5-overexpressing cells, which supports 
the fact that JMJD5 might have a tumor suppressor role in liver cancer. Several cell 
cycle-associated gene sets found to be enriched in EGEM-e1 but not in EGEM-w4 
point to the potential cell cycle regulator role of JMJD5 most probably through 
inhibiting it. 
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Table 4.4: Gene set enrichment analysis of EGEM-w4 and EGEM-e1 with respect to cellular 
processes.  
(50 gene sets are significantly enriched in EGEM-w4, and 68 gene sets are significantly enriched in 
EGEM-e1 with 0.01 p value.) 
Gene sets enriched in EGEM-w4 Gene sets enriched in EGEM-e1 
DOUBLE_STRANDED_RNA_BINDING NUCLEAR_BODY 
RNA_POLYMERASE_II_TRANSCRIPTION_F
ACTOR_ACTIVITYENHANCER_BINDING 
NEGATIVE_REGULATION_OF_CELL_MIG
RATION 
GLUTATHIONE_TRANSFERASE_ACTIVITY HOMEOSTASIS_OF_NUMBER_OF_CELLS 
EXTRINSIC_TO_PLASMA_MEMBRANE PML_BODY 
MONOVALENT_INORGANIC_CATION_HO
MEOSTASIS 
RNA_HELICASE_ACTIVITY 
PROTEIN_TARGETING_TO_MEMBRANE PHOSPHOINOSITIDE_BINDING 
SARCOMERE RESPONSE_TO_ORGANIC_SUBSTANCE 
AXON B_CELL_DIFFERENTIATION 
TRANSFERASE_ACTIVITY_TRANSFERRIN
G_SULFUR_CONTAINING_GROUPS 
CHROMATIN_BINDING 
POSITIVE_REGULATION_OF_EPITHELIAL_
CELL_PROLIFERATION 
DNA_REPLICATION 
RESPONSE_TO_NUTRIENT SMALL_CONJUGATING_PROTEIN_SPECI
FIC_PROTEASE_ACTIVITY 
REGULATION_OF_HEART_CONTRACTION REGULATION_OF_GTPASE_ACTIVITY 
SULFOTRANSFERASE_ACTIVITY NEGATIVE_REGULATION_OF_GROWTH 
MEDIATOR_COMPLEX TRANSCRIPTION_FACTOR_COMPLEX 
AMINO_SUGAR_METABOLIC_PROCESS RNA_DEPENDENT_ATPASE_ACTIVITY 
INTRAMOLECULAR_OXIDOREDUCTASE_A
CTIVITY 
SEQUENCE_SPECIFIC_DNA_BINDING 
PHOSPHATE_TRANSMEMBRANE_TRANSP
ORTER_ACTIVITY 
ATP_DEPENDENT_RNA_HELICASE_ACTI
VITY 
INORGANIC_ANION_TRANSMEMBRANE_T
RANSPORTER_ACTIVITY 
MYELOID_CELL_DIFFERENTIATION 
MYOFIBRIL G1_PHASE 
SH3_SH2_ADAPTOR_ACTIVITY KINETOCHORE 
SECRETIN_LIKE_RECEPTOR_ACTIVITY MITOCHONDRIAL_OUTER_MEMBRANE 
G2_M_TRANSITION_OF_MITOTIC_CELL_C
YCLE 
CHROMOSOMEPERICENTRIC_REGION 
OVULATION_CYCLE PROTEIN_COMPLEX_BINDING 
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CARBON_OXYGEN_LYASE_ACTIVITY REGULATION_OF_RAS_GTPASE_ACTIVI
TY 
SULFUR_METABOLIC_PROCESS POSITIVE_REGULATION_OF_T_CELL_PR
OLIFERATION 
PROTEIN_KINASE_INHIBITOR_ACTIVITY RHO_GUANYL_NUCLEOTIDE_EXCHANG
E_FACTOR_ACTIVITY 
INTEGRIN_COMPLEX MYELOID_LEUKOCYTE_DIFFERENTIATI
ON 
CELLULAR_MONOVALENT_INORGANIC_C
ATION_HOMEOSTASIS 
GLYCEROPHOSPHOLIPID_METABOLIC_P
ROCESS 
LYASE_ACTIVITY ENDOTHELIAL_CELL_PROLIFERATION 
DNA_FRAGMENTATION_DURING_APOPTO
SIS 
SINGLE_STRANDED_DNA_BINDING 
MEMBRANE_FUSION GLUCOSE_CATABOLIC_PROCESS 
KINASE_INHIBITOR_ACTIVITY OXIDOREDUCTASE_ACTIVITY_ACTING_
ON_NADH_OR_NADPH 
SPERM_MOTILITY HEMOPOIESIS 
SINGLE_STRANDED_RNA_BINDING REGULATION_OF_ENDOTHELIAL_CELL_
PROLIFERATION 
POSITIVE_REGULATION_OF_ANGIOGENES
IS 
DNA_DIRECTED_RNA_POLYMERASEII_C
ORE_COMPLEX 
HYDRO_LYASE_ACTIVITY REGULATION_OF_GROWTH 
CONTRACTILE_FIBER REGULATION_OF_DNA_METABOLIC_PR
OCESS 
PROTON_TRANSPORTING_TWO_SECTOR_
ATPASE_COMPLEX 
PHOSPHOLIPID_TRANSPORTER_ACTIVIT
Y 
REGULATION_OF_PH ESTABLISHMENT_OF_ORGANELLE_LOC
ALIZATION 
PROTEIN_SERINE_THREONINE_TYROSINE
_KINASE_ACTIVITY 
ATP_DEPENDENT_HELICASE_ACTIVITY 
LAMELLIPODIUM REGULATION_OF_NEUROTRANSMITTER
_LEVELS 
CELL_PROJECTION CHROMOSOME_CONDENSATION 
INTERCELLULAR_JUNCTION_ASSEMBLY DEOXYRIBONUCLEASE_ACTIVITY 
MICROVILLUS NUCLEOTIDE_KINASE_ACTIVITY 
DEACETYLASE_ACTIVITY HEMOPOIETIC_OR_LYMPHOID_ORGAN_
DEVELOPMENT 
ANION_CATION_SYMPORTER_ACTIVITY RESPONSE_TO_HYPOXIA 
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POSITIVE_REGULATION_OF_CELL_DIFFER
ENTIATION 
MITOCHONDRIAL_MEMBRANE_ORGANI
ZATION_AND_BIOGENESIS 
GLUCOSAMINE_METABOLIC_PROCESS CELLULAR_PROTEIN_COMPLEX_ASSEM
BLY 
VACUOLAR_PART RHO_GTPASE_ACTIVATOR_ACTIVITY 
 REGULATION_OF_MEMBRANE_POTENTI
AL 
 STEROID_BIOSYNTHETIC_PROCESS 
 ALDO_KETO_REDUCTASE_ACTIVITY 
 CELL_SURFACE 
 BIOGENIC_AMINE_METABOLIC_PROCES
S 
 OXIDOREDUCTASE_ACTIVITY_ACTING_
ON_THE_CH_CH_GROUP_OF_DONORS 
 HELICASE_ACTIVITY 
 DNA_DEPENDENT_DNA_REPLICATION 
 FATTY_ACID_METABOLIC_PROCESS 
 OLIGOSACCHARYL_TRANSFERASE_CO
MPLEX 
 BASEMENT_MEMBRANE 
 RUFFLE 
 REPLICATION_FORK 
 G1_PHASE_OF_MITOTIC_CELL_CYCLE 
 GENERAL_RNA_POLYMERASE_II_TRAN
SCRIPTION_FACTOR_ACTIVITY 
 EXTERNAL_SIDE_OF_PLASMA_MEMBRA
NE 
 REGULATION_OF_MYELOID_CELL_DIFF
ERENTIATION 
 INTERLEUKIN_8_BIOSYNTHETIC_PROCE
SS 
 
Gene set enrichment analysis with respect to oncogenic properties is shown in Table 
4.5. Primarily enriched sets are those of p53 and β-catenin targets as expected 
because p53 and β-catenin are the most frequently observed mutations in 
hepatocellular carcinoma [5]. Interestingly, the sets enriched in EGEM-w4 and those 
enriched in EGEM-e1 were quite different from each other except for the sets of p53 
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and β-catenin. In fact, p53 and β-catenin sets were not the same at all. 
“BCAT.100_UP.V1_DN” and “P53_DN.V1_UP” sets were present in EGEM-w4 
list, whereas “BCAT_BILD_ET_AL_DN”, “BCAT_BILD_ET_AL_UP” and 
“P53_DN.V1_DN” were present in EGEM-e1 list. This might indicate that 
expression profiles of cancer-related pathways substantially altered with high levels 
of JMJD5, proposing a possible tumor suppression role for JMJD5.   
Table 4.5: Gene set enrichment analysis of EGEM-w4 and EGEM-e1 with respect to oncogenic 
properties  
(7 gene sets are significantly enriched in EGEM-w4 and 12 gene sets are significantly enriched in 
EGEM-e1 with 0.01 p value.)          
Gene sets enriched in EGEM-w4   
BCAT.100_UP.V1_DN Genes down-regulated in HEK293 cells 
(kidney fibroblasts) expressing 
constitutively active form of 
CTNNB1 gene 
YAP1_DN Genes down-regulated in MCF10A cells 
(breast cancer) over-expressing YAP1 gene  
P53_DN.V1_UP Genes up-regulated in NCI-60 panel of cell 
lines with mutated TP53 
HINATA_NFKB_MATRIX Matrix, adhesion or cytoskeleton genes 
induced by NF-kappaB in primary 
keratinocytes and fibroblasts 
PKCA_DN.V1_DN Genes down-regulated in small intestine in 
PRKCA knockout mice  
ALK_DN.V1_UP Genes up-regulated in DAOY cells 
(medulloblastoma) upon knockdown of 
ALK gene by RNAi  
PRC1_BMI_UP.V1_DN Genes down-regulated in TIG3 cells 
(fibroblasts) upon knockdown of 
BMI1 gene 
Gene sets enriched in EGEM-e1   
CSR_EARLY_UP.V1_UP Genes up-regulated in early serum 
response of CRL 2091 cells (foreskin 
fibroblasts) 
BCAT_BILD_ET_AL_DN Genes down-regulated in primary epithelial 
breast cancer cell culture over-expressing 
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activated CTNNB1 gene  
CORDENONSI_YAP_CONSERVED_SIGNATURE YAP conserved signature 
SIRNA_EIF4GI_DN Genes down-regulated in MCF10A cells vs 
knockdown of EIF4G1 gene by RNAi  
GLI1_UP.V1_UP Genes up-regulated in RK3E cells (kidney 
epithelium) over-expressing GLI1 
BCAT_BILD_ET_AL_UP Genes up-regulated in primary epithelial 
breast cancer cell culture over-expressing 
activated CTNNB1 gene  
RB_DN.V1_UP Genes up-regulated in primary 
keratinocytes from RB1 skin specific 
knockout mice  
CRX_NRL_DN.V1_DN Genes down-regulated in retina cells from 
CRX and NRL double knockout mice 
P53_DN.V1_DN Genes down-regulated in NCI-60 panel of 
cell lines with mutated TP53 
MEL18_DN.V1_UP Genes up-regulated in DAOY cells 
(medulloblastoma) upon knockdown of 
PCGF2 gene by RNAi  
CAHOY_ASTROCYTIC Genes up-regulated in astrocytes 
AKT_UP_MTOR_DN.V1_DN Genes down-regulated by everolimus in 
mouse prostate tissue transgenically 
expressing human AKT1 gene vs untreated 
controls 
 
4.8 Phenotypic Assays for Stable Clones 
In order to have an insight into the function of JMJD5, any phenotypic effect of its 
overexpression in isogenic clones was investigated applying different methods. 
4.8.1 Sulphordamine B Assay for Cell Proliferation 
Figure 4.12 shows SRB results, as an indication of cell growth, for stable clones 
under 6-day doxycycline induction.  
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Figure 4.12: SRB readings of stable clones after 6-day doxycycline induction  
(Mean OD values for triplicate samples are indicated at the bottom of the graph.)  
SRB assay results indicate that doxycycline inhibits growth, decreasing OD level in 
all cells to almost half of Dox (-) case, due to its antibiotic activity. However, it 
seems that wild type clones are slightly more resistant to this drug. OD means of 
clones under Dox (+) conditions are also quite comparable. This result implicates 
that there is no drastic difference between growth rates of isogenic clones. 
4.8.2 Immunofluorescence Double Staining for Bromodeoxyuridine and Flag 
The reason why a substantial growth difference among the clones could not be 
observed quantitatively in SRB assay might be the heterogeneity of the clones for 
JMJD5 positivity. As observed in the previous immunoflorescence data, two type of 
populations, namely Flag-JMJD5(+) and Flag-JMJD5(-) are present in each clone. 
Even there is an effect of JMJD5 overexpression on growth, it may be tiny or 
unnoticeable in those mixed populations because Flag-JMJD5(-) population could 
compensate for that effect. In order to find out any possible effect of JMJD5 on 
EGEM-w2 EGEM-w4 EGEM-m2 EGEM-m3 EGEM-e1 
Dox+ 0,612 0,592 0,549 0,563 0,517 
Dox- 0,890 0,978 1,068 0,943 0,925 
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growth, BrdU incorporation of Flag-JMJD5(+) and Flag-JMJD5(-) cells were 
determined separately. In this case, instead of using Dox (-) cells or mutant cells and 
empty cells as negative controls, Flag-JMJD5(-) cells sitting in the same clonal 
culture and under same doxycycline condition with Flag-JMJD5(+) cells were used 
as negative controls.           
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Figure 4.13: BrdU and Flag double immunoflorescence staining pictures and merged photos for 
each isogenic stable clone  
(Images were taken at 20X.) 
It can be seen from Flag + DAPI merged images that Flag and DAPI signals 
colocalize, suggesting that the JMJD5 localization region in the cell is nucleus. By 
counting the cells manually on each picture in Figure 4.13, several parameters were 
calculated as shown in the following bar graphs. First, BrdU and Flag positivities for 
each clone are depicted in Figure 4.14.       
 
Figure 4.14: BrdU and Flag positivity percentages for each isogenic clone  
(At the bottom of the graph, the percentage values are indicated.)  
Accordingly, Flag positivity of the clones varies greatly, and there is a decreasing 
tendency in BrdU positivity from wild type to mutant and empty clones. Since the 
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Flag expression is variable, and the populations are not homogenous, this tendency 
of fall may not be dependent on type of constructs or JMJD5 levels.  
On the other hand, Figure 4.15 shows the BrdU incorporation change depending on 
Flag expression in the same clone. According to this result, BrdU+ cell percentage in  
 
Figure 4.15: BrdU positivity for Flag-JMJD5 (+) and Flag-JMJD5 (-) subpopulations of each 
clone.  
(The percentages are indicated at the bottom of the graph.)  
wild type clones decreases 7 % in EGEM-w2 but increases 18 % in EGEM-w4. In 
mutant clones, there is a 17 % increase in EGEM-m2, while there is an 8 % decrease 
in EGEM-m3. However, it seems that the changes in BrdU positivity between Flag-
JMJD5 (+) and Flag-JMJD5 (-) populations are inconsistent and not substantially 
different. As a result, BrdU double staining results show the nuclear localization of 
JMJD5 protein; however, JMJD5 seems to be ineffective on cell growth. 
4.8.3 Cell Cycle Analysis by Flow Cytometry 
As our cell lines were heterogenous in terms of ectopic JMJD5 expression, we 
perfomed cell cycle analyses on JMJD5-positive and JMJD5-negative cells of the 
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same cell populations by double staining with anti-flag antibody and propidium 
iodide. Flow cytometry procedure with EGEM-w4, EGEM-m2 and EGEM-e1clones 
was applied to find out any phenotypic clue in cell cycle patterns of JMJD5-
overexpressing clones. In Table 4.6, FITC signals of the clones and isotype control 
are shown. Isotype control has a very low FITC signal, whereas EGEM-e1 has 
relatively considerable background signal compared to isotype. EGEM-w4 and 
EGEM-m2 samples, on the other hand, have about 4-fold higher FITC signal than 
EGEM-e1, indicating the presence of Flag-JMJD5 expressing cells in the 
populations. Using the EGEM-e1 background signal as a threshold, a subpopulation 
of cells with higher FITC than threshold value were gated and further analyzed for 
DNA staining. The cell cycle patterns and average percent distributions for each 
cycle phase are illustrated in Figure 4.16 and Table 4.7, respectively. According to 
the quantitative distribution result, in both mutant and wild type clones, there are 
mild decreases in G1 and S phases. In contrast, G2/M phase cell fraction was raised 
from 16.3% in control clones to 20.4 and 19.3 % in wild-type and mutant JMJD5 
clones, respectively. Thus there was 25% and 18% increase in wild-type and mutant 
JMJD5 clones, respectively. This slight change might be important in shedding light 
on the role of JMJD5 in liver cancer. Furthermore, it seems that this change is 
independent of H321A mutation in Jumonji C domain. 
 Table 4.6: Mean FITC signals for the clones and isotype control    
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Figure 4.16: Cell cycle analysis for stable clones  
(Horizontal axis indicates propidium iodide signal in logarithmic scale, while vertical axis indicates 
the number of cells in linear scale. The results are triplicate for EGEM-w4 and EGEM-e1 but 
duplicate for EGEM-m2. The percentage of cells in each cell cycle phase are indicated on the graphs.)   
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Table 4.7: The average percentage distribution of isogenic clones in cell cycle phases 
 
4.9 Analysis of Isogenic Sub-clones with High JMJD5 Expression  
The effects of JMJD5 overexpression on phenotype, proliferation and cell cycle 
patterns of stable clones were either mild or unnoticeable. This could be due to a lack 
of effect due to JMJD5 expression or alternatively the partially positive expression of 
ectopic JMJD5 could hinder any potentially important effect. In order to increase the 
positivity of JMJD5, wild type and mutant stable clones were seeded in very low 
densities and allowed to form single positive colonies under optimal 9 µg/ml 
puromycin selective pressure. From this strategy, it was expected that single clones 
with 100 % JMJD5 positivity could be obtained. After a few-week selection, the 
emerging single cell-derived colonies were isolated, further grown in bigger plates 
and tested for JMJD5 positivity. 
4.9.1 Immunoperoxidase Staining Analysis    
In Figure 4.17, immunoperoxidase staining with Flag monoclonal antibody for some 
of the isolated stable clones is illustrated. All of the clones were induced with 
doxycycline for 48 hours.   
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Figure 4.17: Immunoperoxidase staining for isolated sub-clones of EGEM-M2 and EGEM-W4 
stable clones  
(The images of EGEM-M2 sub-clones were taken at 40 X, while those of EGEM-W4 were taken at 20 
X. For each sub-clone, triplicate images are shown.)    
Despite the expectation of obtaining sub-clones with full JMJD5 positivity, the 
staining result indicates that the positivity increases greatly but not reaching to 
hundred percent. As shown in Figure 4.17, not only the percentage of exogenous 
JMJD5 expression but also the level of expression changes between clones and even 
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between the cells. Higher positivity and expression level are observed in EGEM M2-
C4 clone compared to others. In order to quantitatively determine the JMJD5 
positivity, JMJD5 (+) cells were counted and percentages were calculated as depicted 
in Table 4.8. 
Table 4.8: Immunoperoxidase count data and the mean Flag-JMJD5 positivity of isolated stable 
sub-clones                           
 
According to the counting results, percentage of Flag-JMJD5 positivity in sub-clones 
changes between 59 % and 82 %. It means that exogenous JMJD5 expression 
substantially increased from 40-50 % up to 60-80 % in these clones. Using those 
newly-isolated sub-clones of high positivity in later assays, the phenotypic effect of 
JMJD5 overexpression or mutation could be better estimated.  
4.9.2 Wound Healing of Stable Sub-clones 
Wound healing capacity of the cells gives an insight into their migration. As the 
migration ability of the cells increase, they close the wound faster. In order to 
investigate the contribution of JMJD5 overexpression to this property in our clones, 
wound healing assay was applied, and the results are shown in Figures 4.18 and 4.19.     
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Figure 4.18: Wound healing of stable clones at 0, 24 and 48 hours  
(The images were taken at 10 X.)  
According to this figure, SNU449-TRex and EGEM-e1 cells close the wound 
quickly, with a very small gap at the end of 24 hours and a complete closure at the 
end of 48 hours. However, the wound healing rates in the wild type and mutant 
isogenic sub-clones are quite similar but much slower relative to SNU449-TRex and 
EGEM-e1 cells. The gaps are still quite large and clearly detectable even after 48 
hours. In Figure 4.19, crystal violet staining of the cells after 48 hours is pictured. 
This figure better compares the scar-closing efficiency of the clones.             
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Figure 4.19: Wound healing of stable clones after 48-hour incubation  
(The cells were stained with 2 % crystal violet, and images were taken at 10 X.)  
The wound healing assay results indicate that the migration ability of mutant and 
wild type clones is much slower than empty and SNU449-TRex clones, proposing 
that JMJD5 protein might decelerate the motility capacity of a tumor regardless of 
H321A mutation.  
4.9.3 Anchorage-independent Growth of Stable Sub-clones 
Soft agar colony formation assay was performed to assess the effect of JMJD5 on 
anchorage-independent growth of stable clones. Immortal cell lines normally cannot 
grow in agar or agarose media because of the requirement of solid attachment to a 
surface. However, when these cells are exposed to activities of oncogenes or 
carcinogens, they are able to grow in these fluidic media without presence of 
attachment to a surface. This assay stringently gives clue about the transformation of 
the cells into malignancy, and it is also regarded to indicate the in-vivo 
carcinogenesis potential of cells.  
Soft agar results of stable JMJD5 clones are indicated in Figure 4.20. The picture of     
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Figure 4.20: 4X, 10X and 20X pictures of formed colonies for stable clones on soft agar 
plates were taken under inverted light microscope at 4X, 10X and 20X. Despite the 
presence of size differences among the clones, all of them were able to produce 
colonies in soft agar. The morphology of the colonies was similar. According to the 
represented images of each clone, EGEM W4-C3, EGEM M2-C2 and EGEM M2-C4 
appeared to form larger and visible colonies, whereas EGEM W4-C2 and EGEM-E1 
clones seemed to form smaller and hardly noticeable colonies. The colony size 
seemed to be increasing from empty to wild type and from wild type to mutant 
clones.   
To obtain reproducible results, two successive experiments with two biological 
replicates for each clone were performed; comprising four biological replicates four 
each clone in total. In order to better quantify the colony formation, colony number 
in 11 represented regions of four replicates for each clone was counted under 
inverted light microscope at 4X considering the colonies in different layers, and their 
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mean colony number fold changes were calculated (Figure 4.21).  
 
Figure 4.21: Mean colony number fold change of isogenic clones with respect to EGEM-e1 
(empty) clone.  
(Paired two-tailed t test with n = 11; *p < 0.05 and **p < 0.001)  
As shown in Figure 4.21, EGEM-E1 had the lowest colony formation with 
designation of 1 fold change. EGEM M2-C2 and EGEM M2-C4 reached the highest 
mean colony numbers, being statistically significant compared to all wild type and 
empty clones. EGEM W4-C2 and EGEM W4-C3 clones formed the intermediate 
number of colonies, being statistically significant compared to empty clones. To sum 
up, soft agar assay indicated that mutant stable sub-clones had the largest size and 
highest number of colonies, wild type clones had the intermediate size and number of 
colonies, and empty clone had the lowest values for both.               
4.9.4 Cell Cycle Analysis of Isogenic Sub-clones by Flow Cytometry 
Cell cycle patterns of isolated sub-clones were also analyzed with FACS method to 
check whether the mild changes in cell cycle distribution of the cells observed in 
Figure 4.16 are also present in isogenic clones with higher JMJD5 levels. Table 4.9 
E1 W4-C2 W4-C3 M2-C2 M2-C4 
Fold change 1 3,4 3,9 7,3 6,8 
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compares mean FITC signals detected for each stable clone, sub-clone and isotype 
control.  
Table 4.9: Mean FITC signals for the isogenic stable clones and isotype control 
 
The increase in JMJD5 positivity observed in immunoperoxidase staining results was 
also confirmed with FITC signals in this table. FITC signals of the sub-clones 
isolated from EGEM-w4 and EGEM-m2 clones were about 1.5 – 2 times higher than 
the original clones. The signal from EGEM-e1 clone was considered as a background 
signal, and the cells having higher signals than this level were gated as JMJD5 
positive cells. Then, the cell cycle distributions of these positive cells were 
particularly investigated, and the results are indicated in Figure 4.22.             
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Figure 4.22: Cell cycle analysis for unsynchronous isogenic sub-clones  
(Horizontal axis indicates propidium iodide signal in logarithmic scale, while vertical axis indicates 
the number of cells in linear scale. The results are triplicate for each clone. The percentage of cells in 
each cell cycle phase are indicated on the graphs.) 
Using the percentages on each graph, the mean distribution percentages were 
calculated as shown in Table 4.10. The mild changes in G1 and G2/M distributions 
Table 4.10: The mean percent distributions of stable clones in cell cycle phases  
 
of low expression clones relative to the empty clone developed  remarkably in high 
expression clones. When compared to control clone, two wild-type JMJD5-
overexpressing clones displayed consistent increase in G2/M phase cells going from 
16.5 % to 23.8 % on average. This represents a 44% increase in wild-type JMJD5-
overexpressing clones. There was also a consistent increase of about 35% in G2/M 
cells in mutant JMJD5-expressing clones. This was accompanied with a decrease in 
G1 phase cells. 
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4.9.5 Sensitivity of Stable Clones to Adriamycin 
Adriamycin, also known as Doxorubicin, is a drug widely used in cancer 
chemotherapy. It inhibits DNA replication by intercalating double strand and 
stabilizing topoisomerase II complex [42, 43]. Consistent with our hypothesis, 
wound healing and FACS results, it can be suggested that JMJD5 could play a role in 
G2 arrest as a tumor suppressor. The tumor suppressor effect of JMJD5, if present, 
could be improved using another growth inhibitor which acts on another arrest 
mechanism if the interaction is synergistic. Hence, the sensitivity of the stable clones 
induced with doxycycline for 72 hours to various concentrations of adriamycin was 
investigated using SRB method. Figure 4.23 and 4.24 show the survival of clones in 
both qualitative and quantitative terms, respectively.   
 
Figure 4.23: SRB staining of isogenic clones under different adriamycin concentrations on 96-
well plates 
78 
 
 
Figure 4.24: Survival curves of stable clones with respect to adriamycin concentration 
According to the picture and the graphical representation, there is no considerably 
important difference between empty, wild type and mutant clones in terms of 
survival. SNU449-TRex cells, however, are more resistant to this drug than all other 
clones. The conclusion from this assay is that the sensitivity of isogenic clones is not 
affected by adriamycin treatment. 
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CHAPTER 5 
DISCUSSION 
Two preliminary studies done by our past and current group members showed 
JMJD5 downregulation in HCC. One of them was an in silico microarray analysis 
showing the smooth downregulation of JMJD5 through the increased disease stages 
of liver. The other study compared HCC and cirrhotic tissue sample pairs of 15 
patients and revealed that JMJD5 levels reduced in HCC relative to cirrhosis in most 
of the patients. Two relatively recent studies on lung cancer and Blm-deficient mice 
also considered JMJD5 as a potential tumor suppressor gene [31, 32]. Referring to 
the preliminary data and literature information, in this study, it was hypothesized that 
JMJD5 might act as a tumor suppressor in liver, resulting in the development of 
cancer upon its deficiency or loss. This hypothesis was tested by applying several 
phenotypic, molecular biological and genetic techniques on SNU449-TRex 
mesenchymal-like liver cancer cell line model.            
5.1 The role of JMJD5 in cell proliferation and cell cycle 
Despite the several lines of evidence about tumor suppression activity of JMJD5, the 
counter argument is also equally supported by an important number of reports. 
Activating cyclin A1 expression, JMJD5 was argued to stimulate cell cycle 
progression of breast cancer cells [27]. In mice embryos, downregulation of p53-p21 
axis was detected, suggesting an oncogenic role for JMJD5 [29, 30]. In order to find 
out an answer to this controversial issue, expression profiling and certain phenotypic 
assays showing a direct measure for cell growth were performed. 
Microarray results were assessed, firstly, in this respect. Gene set enrichment 
analysis depending on cellular processes, shown in Table 4.4, indicated that several 
growth pathways are active in control cells, consistent with the nature of cancer cells. 
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However, the number of those active growth gene sets diminished in wild type cells. 
This result suggests that several growth genes and pathways might be downregulated 
under high levels of JMJD5, addressing JMJD5 as a potential critical regulator on 
several cell cycle and cell division mechanisms. The effects of JMJD5 on cell growth 
were further investigated using different methodologies.                 
SRB and BrdU incorporation assays were carried out for this purpose. In SRB 
experiment, the quantitative readings did not differ considerably between wild type, 
mutant and empty stable clones. However, one cannot claim that JMJD5 has no 
influence on HCC cell growth by only considering this data because of the 
heterogeneity of the clones for exogenous JMJD5 expression. Due to the 
heterogeneity, a portion of cells in the population which have strong JMJD5 levels 
might affect the tumor growth in some way, but this effect may not be noticed in the 
total population because of abundant negative cells. Those negative cells might be 
neutralizing the overall phenotype of the cells. Hence, BrdU and flag double staining 
strategy was followed to compare the BrdU incorporation rates of Flag-JMJD5 (+) 
and Flag-JMJD5 (-) cells in the same culture. Although there were drastic changes 
between the BrdU positivity of Flag (+) and Flag (-) cells within the same clone, they 
were not following a consistent pattern. A substantial incline in BrdU positivity 
occurred in a wild type or mutant clone, whereas a substantial decline occurred in the 
other wild type or mutant clone. That is, the results of the same type of clones were 
inconsistent. Because of this inconsistency, the BrdU changes could not be attributed 
to overexpressed JMJD5 gene. As a result, these assays were inconclusive in giving a 
clue on cell proliferation effect of JMJD5. To better compare the cell proliferation 
differences between JMJD5 wild type, mutant and empty clones; SRB assay could be 
repeated with high expression isogenic clones, and BrdU signal could be measured 
by FACS device, giving a more reliable quantitative result instead of counting with 
naked eye. 
In the literature, several studies have reported JMJD5 as a cell cycle regulator in a 
H3K36me2 demethylase dependent manner. In breast cancer, induction of cyclin A1 
expression by JMJD5 was shown [27].  In mouse embryos, JMJD5 was found to 
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have essential developmental functions through inhibition of p53-dependent cell 
cycle arrests and downregulation of p21 cyclin-dependent kinase inhibitor [29, 30].  
In microarray data, Wnt signaling pathway components were found to be altered in a 
way that increases Wnt signaling under JMJD5 induction. Retinol metabolism 
components were also significantly upregulated under high levels of JMJD5. These 
pathways have been shown to be involved in developmental processes [44, 45]. 
Particularly Wnt, have important activatory roles in cell-cell communication, cell 
proliferation, differentiation and migration [45]. In addition, cellular differentiation 
and G2-M transition gene sets were detected to be enriched in EGEM-w4. Most 
interestingly, gene set enrichment analysis in empty clone gave several cell cycle 
progression and DNA replication-related processes, meaning they are abnormally 
active in liver cancer cell model. However, in wild type clone, the analysis results did 
not indicate most of those cell cycle-related pathways. All the literature knowledge 
and microarray results, collectively, point to a critical role of JMJD5 in the cell cycle 
and development of the organism.        
Cell cycle analysis was applied to have an insight into the function of JMJD5 on the 
regulation of cell cycle. As a potential tumor suppressor, whether it blocks, 
decelerates or leads to an accumulation in any phase of the cell cycle was assessed 
using unsynchronized SNU449-TRex clones. Most noticeable result was that in 
JMJD5 stable clones cell distribution in G1 phase decreased remarkably, while that 
in G2/M phase increased remarkably. This change was more strongly observed as the 
level of JMJD5 expression increased in the sub-clones, strongly suggesting the role 
of JMJD5 on this phenotype. Based on this observation, it can be proposed that 
JMJD5 might play a cell cycle regulatory role in two ways. One way is that JMJD5 
might be acting as an activator of cell cycle, facilitating the passage of G1/S and 
G2/M phases. Since many reports have indicated its cell cycle-activating role and 
requirement for developmental processes, this alternative role seems to be plausible.  
The other alternative way is that JMJD5 might play an inducer role in G2/M cell 
cycle arrest mechanisms. MCF7 breast cancer cells underwent G2/M arrest upon 
silencing of JMJD5, exhibiting the similar phenotype to our cells  with a substantial 
decrease in G1 and S cell percentage but a substantial increase in G2/M cell 
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percentage [27]. It is also possible that JMJD5 might be acting differently depending 
on the context; meaning that it may be a cell cycle activator in embryos or in 
progenitor cells, whereas it may be a cell cycle blocker in adult cells. Additionally, it 
may behave as a cell cycle activator in breast cancer but as a suppressor in liver 
cancer. The absence of cell cycle progression-associated gene sets under JMJD5 
induction also supports its suppressor effect on cell cycle of liver cancer cells. To 
better understand cell cycle regulation in SNU449 cells under JMJD5 
overexpression, further analyses could be done by using synchronized cells.                       
5.2 Role of JMJD5 in cell migration and morphology  
As in the case of many types of cancer, metastasis and malignant cell transformation 
make critical contributions to the development of liver cancer. Invasion and 
metastasis is one of the hallmarks of cancer [46]. Poorly differentiated HCC tumor 
has metastasis property [7]. Therefore, to make an inference on effect of JMJD5 on 
metastasis, migration of SNU449 cells under the effect of upregulated JMJD5 was 
investigated.  
In relation to metastasis, microarray study detected an upregulation in FAP 
(fibroplast activation protein alpha), which is known to be upregulated in epithelial 
cancers and associated with epithelial-mesenchymal interactions (from NCBI-Gene); 
and also a downregulation in CDH4 (cadherin 4), a typical cadherin from cadherin 
superfamily involved in brain segmentation and neuronal outgrowth (from NCBI-
Gene). Importantly, a gene set responsible for positive regulation of epithelial cell 
proliferation were shown to be enriched in JMJD5-overexpressing cells. NF-KB 
target genes involved in matrix, adhesion and cytoskeleton were also shown to be 
increased in wild type cells. Considering all these data, microarray results imply a 
potential function of JMJD5 in epithelial-mesenchymal transitions, in favour of 
epithelial characteristics.  
Wound healing capacity is an indication for the migration of tumor cells. According 
to the results of the assay, the motility of the cells decreases as JMJD5 levels 
increase regardless of mutation in JmjC domain. This points out to the tumor 
suppressor role of JMJD5 as stated in the hypothesis. SNU449 cells, corresponding 
83 
 
to a considerably high grade of HCC tumor, have mesenchymal-like metastatic 
features. We would like to add here some reserves to our observations. Our observed 
decreased mobility in the presence of JMJD5 has not yet been confirmed by an 
independent laboratory (Prof. Neşe Atabey, personal communication). If our 
observations are confirmed, the decline observed in this property could be possibly 
explained by the increase in their epithelial features. The expression changes 
summarized above might be underlying this phenotypic alteration. As suspected 
molecular mediators, expression of these factors could be further investigated in 
protein and RNA levels upon JMJD5 overexpression. Additionally, the markers of 
mesenchymal to epithelial transition should also be checked. Interestingly, despite 
the drastic change in migratory phenotypes between the clones, no noticeable 
morphological difference was observed.  
5.3 Role of JMJD5 in anchorage-independent colony formation 
Liver injury followed by genomic instability loss is an early event in HCC 
development, leading to turning of normal hepatocytes into malignant phenotypes [6, 
7]. Hence, to gain an insight into effect of JMJD5 on malignant transformation, 
anchorage-independent colony formation of SNU449 cells under the effect of 
upregulated JMJD5 was investigated. 
Colony formation capacity of the JMJD5 stable clones was tested by soft agar assay. 
Intriguingly, mutant cells had the highest colony formation capacity, wild type cells 
had the intermediate capacity, and empty cells were the least capable clone among 
them. This result suggests that JMJD5 overexpression induces anchorage-
independent growth and might increase tumorigenecity, mutant clone having the 
greatest effect. In contrast to the wound healing outcomes, soft agar assay implicates 
a possible oncogenic role for JMJD5. These seemingly contradictory results may be 
explained by the potential diversity of JMJD5 targets, as a histone demethylase in 
chromatin and as a protein hydroxylase in soluble nucleus [26]. Its presence in both 
cytoplasm and nucleus was detected in A. thaliana, suggesting dual functions 
depending on cellular location [25]. Putative interacting motifs detected on JMJD5 
for nuclear receptor and methyltransferase binding also suggest participation into 
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complex biological networks [27]. It could briefly be stated that JMJD5 may play a 
tumor suppressor or tumor inducer role depending on context, location and 
interacting partners, affecting the overall phenotype. Assuming that JMJD5 increases 
epithelial characteristics, another reason could be that JMJD5-overexpressing cells 
tend to grow in close proximity, forming clumps due to the strong cell to cell 
adhesion. Hence, it should be noted that JMJD5 might seem to have induced tumor 
growth in soft agar assay due to increasing the expression of epithelial genes rather 
than carrying an oncogene property.      
5.4 JMJD5 and drug sensitivity 
Adriamycin, also known as doxorubicin, is a drug widely used in chemotherapy of 
many cancers. It acts through intercalation of DNA and stabilization of 
topoisomerase II complex, preventing replication of DNA and arresting the cells in S 
phase [42, 43].  
It was estimated according to our experimental results that JMJD5 could be a 
potential tumor suppressor through arresting the cell cycle at G2/M phase. Since 
adriamycin is known to block cell cycle at S phase, JMJD5-overexpressing cells 
were thought to be possibly more sensitive to adriamycin treatment than empty cells. 
Contrary to this expectation, there was no considerable difference between the 
survival of mutant, wild type and empty clones. This could be due to the fact that the 
effect of JMJD5 upregulation on cell cycle arrest is so tiny that it is dominated by 
that of adriamycin. Since it is very effective on cells, even very low doses of 
adriamycin may be enough to arrest all the cells without any contribution of JMJD5.         
5.5 The importance of H321A mutation in JmjC domain  
Histidine-321 (His-321) amino acid is located in the catalytic site of JMJD5, and 
plays a critical role in coordination of Fe (II) with Asp-323 and His-400 [28]. It was 
shown that JMJD5could not carry out its demethylation activity on H3K36me2, and 
all the biological effects of wild type JMJD5 overexpression were reversed upon 
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H321A mutation, emphasizing the importance of His-321 residue in biological 
function of the protein [27].  
Knowing the crucial role of it, the effects of H321A mutation on the phenotype and 
the activity of JMJD5 was also investigated in our experiments. In wound healing, 
flow cytometry, adriamycin sensitivity and cell proliferation assays, no phenotypic 
difference was detected between wild type and mutant clones of JMJD5. To be 
certain about unchanged phenotypes, these assays could be repeated. However, based 
on these observations, it can be said that H321A mutation, despite disrupting histone 
demethylase activity, does not influence histone demethylase-independent functions 
of JMJD5. Apparently, differential histone demethylase activity of wild type and 
mutant clone does not create any phenotypic changes detectable with these methods. 
The phenotypic changes observed in both wild type and mutant cells compared to 
empty cells are most probably caused by histone demethylase-independent functions 
of JMJD5. Interestingly, mutant and wild type clones significantly differed in their 
colony formation capacities in soft agar. Mutant clone appeared to form larger and 
greater number of colonies than wild type clone. This result suggests that H3K36me2 
demethylase activity plays a role, to some extent, in prevention of anchorage-
independent growth through yet unknown downstream interactions. Upon its loss, 
cells seem to gain more aggressive and tumorigenic character. Therefore, it can be 
said that JMJD5 has a partial tumor inhibitory role via its JmjC histone demethylase 
activity.                    
5.6 JMJD5 as a tumor suppressor in the pathogenesis of HCC   
In this study, the relationship of JMJD5 with development of liver cancer was 
investigated applying several methods. Although JMJD5 could not be associated 
with a specific function in liver cancer, there is sufficiently high number of data to 
make an inference on the role of JMJD5 in liver tumor growth. Analysis of 
expression profiles showed that cell cycle-activating genes are less active, genes 
responsible for differentiation and genes giving rise to epithelial characteristics are 
upregulated in wild type cells compared to empty cells. Among our in vitro studies, 
two types of responses were consistently associated with JMJD5 overexpression: (1) 
86 
 
Increase in the fraction of G2/M phase cells; (2) increased anchorage-independent 
colony formation ability. We do not know how these changes will affect HCC tumor 
growth. The increase in G2/M phase cells could indicate increased mitotic activity 
which is positively correlated with tumor growth. The increase in anchorage-
independent colony forming ability is used as an in vitro test for in vivo tumorigenic 
potential of cancer cells [47]. Thus, the overexpression of JMJD5 in HCC cells could 
also promote in vivo tumor growth. Primarily, these two effects would indicate a 
tumor promoting activity of JMJD5 expression in HCC tumors. However, this is not 
compatible with the decreased expression of JMJD5 in tumor cells. Microarray data 
itself may be misleading because it represents an increase in JMJD5 transcription, 
rather than an overexpression of JMJD5 protein. Our western blot experiments 
comparing cirrhosis and HCC provided a mixed response. Although most HCCs 
displayed a decreased expression, some others displayed no change or even an 
increased expression. This could be due to different activities of JMJD5 protein as 
evidenced by the fact that it may either function as a HDM or a protein hydroxylase 
[26]. These two independent activities may affect tumor outcome differently 
depending on the cellular environment. The activity of many proteins is controlled by 
cellular localization and protein-protein interaction which may confer differential 
abilities to these proteins. An excellent example for this is β-catenin.  
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CHAPTER 6 
CONCLUSION 
In this study, several consistent results were obtained from in vitro experiments as 
well as some inconsistent results.  First, BrdU incorporation rate and S phase fraction 
did not change. Second, cells in G2/M are up, G1 cells are down. This can be due to 
accumulation of cells at G2 or M phase or a change in the progression during cell 
cycle: acceleration of G1 events so there is less G1 cells, or slowing down at G2 
phase or partial arrest in M phase. But these changes did not affect cell proliferation 
rates. What it means is not known yet. Third, there was an increase in anchorage-
independent colony formation. This definitely points to a promalignant change which 
may indicate better tumor growth in vivo. Still, this remains to be demonstrated in 
nude mice experiments. On the other hand, despite observing decreased cell motility, 
this has not been confirmed by another lab. It should be confirmed by further 
experiments in order to have a better comment on this data. Differences between 
wild-type and mutant are also not consistent, so this mutation may have no 
differential effect compared to wild-type JMJD5 with our tests. Somewhat in vitro 
data is not compatible with a tumor suppressor effect as suggested by decreased 
transcript expression. WB data did not show consistent decreased protein expression 
either, some tumors even expressing more. JMJD5 may be a tumor suppressor or 
promoter depending on HCC type, or cell type. Beta-catenin is a good example for 
this. It promotes tumor growth when accompanied by TCF factors in nucleus, but has 
an opposite effect as a component of E-cadherin cell-cell adhesion complex [48]. 
Thus, JMJD5 as an HDM or protein hydroxylase may have different effects some 
serving as tumor promoter, others tumor suppressor. 
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CHAPTER 7 
FUTURE PERSPECTIVES 
In vitro experiments on mesenchymal liver cancer cell line SNU449 suggested that 
JMJD5 might be a tumor promoter or suppressor. To provide definite conclusions for 
this question, two types of main experiments are missing: (1) in vitro effects of 
JMJD5 knock-down, (2) in vivo effects of both JMJD5 overexpression and knock-
down. 
Since JMJD5 seems to be downregulated from normal liver to HCC, silencing of it in 
the liver cells could lead to carcinogenesis. JMJD5 knock-down via siRNA or 
shRNAs should first be tried with cell lines which express JMJD5 in sufficiently high 
levels. After transiently or stably-knocked down cell lines are created, similar 
phenotypic assays should be performed to determine its effects on the cells. 
As shown in this study, JMJD5 seems to alter migration and anchorage-independent 
growth of the cells, suggesting a potential link between JMJD5 and in vivo 
metastasis and carcinogenesis. Using these clones, xenograft liver cancer models 
could be created in mice, and their metastatic behavior and tumorigenic potential 
could be investigated under in vivo conditions. For in vivo-silencing, conditional 
knock-out mice for JMJD5 are required because JMJD5-deficient mice are 
embryonic lethal [29]. When it is knocked out, the phenotypic, morphological and 
biochemical changes in the liver could be traced. 
In addition, cell growth assays and methodologies applied in this study, such as SRB 
staining and BrdU incorporation, were not very certain in determining growth 
promotion or inhibition of stable clones with low JMJD5 expression. These assays 
could be repeated with high expression clones to gain a better insight into growth 
phenotype of the cells. In this case, instead of counting BrdU(+) cells with naked 
eye, FACS technique could be used to detect the BrdU signal in quantitative terms. 
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Commercial kits, such as MTT and XTT cell proliferation assay kits, could also be 
used for more accurate results. In order to confirm that JMJD5 acts on blocking or 
accelerating cell cycle, flow cytometry assays can be repeated with synchronized 
cells. Alternatively, expression levels of proteins known to be involved in G1/S 
transition or G2/M arrest could be detected and compared between JMJD5-
overexpressing cells and empty cells.  
According to the microarray analysis results and cell migration results, it seems that 
JMJD5 activates certain genes responsible for epithelial characteristics and cellular 
differentiation, probably causing the decrease in migratory property of the cells. 
Whether the levels of these genes are changing in RNA and protein levels could be 
checked. Additionally, the change in mesenchymal to epithelial transition markers 
should also be investigated. 
To sum up, JMJD5 could be a promising therapeutic or biomarker target in liver 
cancer research; hence, further studies are needed to comprehensively understand the 
biological role of it in HCC. 
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